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The main aim will  be to  find susceptibility  profiles  of  biofilms of  non-
albicans Candida species - Candida krusei, Candida guilliermondii  a  Candida 
lusitaniae  to  echinocandins. There  will  be  tested  caspofungin,  micafungin 
a anidulafungin.
Clinical isolates will be gathered from the National Collection of Fungal 
Pathogens stationed at the Microbiology Department, Medical School, National 
and Kadodistrian University of Athens. 
Experimental part will be expand with a review focused on echinocandins 
and Candida biofilms.
The thesis will be written in English.
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Zadání diplomové práce
Cílem  experimentální  práce  bude  zjistit  citlivost  biofilmů  non-albicans 
Candida druhů k vybraným echinokandinům. Budou testovány Candida krusei,  
Candida guilliermondii  a  Candida lusitaniae. Z echinokandinů budu testovány 
caspofungin, micafungin a anidulafungin.
Budou použity klinické izoláty pocházející z National Collection of Fungal 
Pathogens umístěné na oddělení mikrobiologie Medical School na National and 
Kadodistrian University of Athens. 
Experimentální práce bude doplněna rešerší na téma echinokandiny a 
kvasinkové biofilmy.
Diplomová práce bude sepsaná v anglickém jazyce.
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Supervisor: Ing. Lucie Křivčíková
Diploma Thesis:    Susceptibility profile of biofilms of non-albicans
                              Candida spp. to echinocandins
Yeasts of the genus Candida are one of the most frequent human fungal 
pathogens. Infections caused by them are related to a specific form of growth – 
biofilm  (BF),  which  has  increased  their  resistance  to  antifungal  treatment. 
Since bloodstream  infections  caused  by  non-albicans  Candida species  are 
increasing, it is important to focus on their susceptibility characteristics.
The main aim of our experiment was to examine the susceptibility profiles 
of  BF  produced  by  rare  non-albicans Candida species  to  echinocandins. 
We tested 3 species of the genus Candida – C. lusitaniae, C. guilliermondii and 
C. krusei and  3 different  echinocandins  –  anidulafungin (AND),  caspofungin 
(CAS)  and  micafungin  (MFG).  Echinocandins  have  unique  mechanisms 
of action.  They  inhibit  the  function  of  the  enzyme  β-1,3-glucan  synthase. 
Disruption of its function leads to inhibition of β-1,3-glucan production, damage 
of fungal cell wall and loss of viability of the cell. 
In  experimental  part  we  used  YNB medium and  RPMI  1640 medium 
to grow Candida species BF and planktonic cells (PL). We incubated both BF 
and PL in 96-well microtiter polystyrene plates. Antifungal activity was assessed 
by  the   2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide 
(XTT) metabolic assay. Each drug concentration was processed in pentaplicate 
for each isolate. 
Results indicate that MFG have the lowest MIC50 and that it is the most 
efficient  drug  to  all  tested  species.  MFG to  BF formed by  C. krusei (MIC50 
0.125 mg/L)  was  most  efficient,  followed  by  C. guilliermondii (MIC50 2 mg/L) 
and less susceptible C. lusitaniae BF (MIC50 16 mg/L). AND was most efficient 
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against C. krusei BF (MIC50 0.125 mg/L), then C. guilliermondii (MIC50 4 mg/L) 
and C. lusitaniae (MIC50 >256 mg/L). CAS was most efficient against C. krusei 
BF  (MIC50  1 mg/L),  then  against  C. guilliermondii (MIC50 32 mg/L)  and 
C. lusitaniae (MIC50 32 mg/L).
In the conclusion of our project we pronounced our findings stating that 
echinocandins  seem  to  be  efficient  against  non-albicans  Candida  biofilms 
in vitro. Biofilm was more resistant to echinocandins than planktonic cells.
Key words: echinocandins, biofilm, Candida, resistance, XTT
10
Abstrakt
Univerzita Karlova v Praze
Farmaceutická fakulta Univerzity Karlovy v Hradci Králové 
Katedra biologických a lékařských věd
Kandidátka: Pavla Pešková
Školitelka: Ing.  Lucie Křivčíková
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Kvasinky rodu  Candida jsou jedny z nejčastějších lidských houbových 
patogenů. Jimi zapříčiněné infekce jsou spojené s výskytem specifické formy 
růstu zvané biofilm (BF), která vykazuje zvýšenou rezistenci vůči antimykotické 
léčbě.  Jelikož systémové infekce způsobené non-albicans Candida druhy se 
v posledních letech vyskytují stále častěji, je potřeba se zaměřit na zkoumání 
jejich citlivosti k různým antimykotikům. 
Hlavním cílem naší práce bylo zjistit citlivost biofilmů (BF) non-albicans 
Candida druhů  k  vybraným echinokandinům.  Testovali  jsme 3  druhy z  rodu 
Candida  –  C. lusitaniae,  C. guilliermondii a  C. krusei a  3  echinokandiny  – 
anidulafungin (AND), caspofungin (CAS) and micafungin (MFG). Echinokandiny 
mají  jedinečný  funkční  mechanismus.  Inhibují  funkci  enzymu  β-1,3-glukan 
syntetázy.  Poškození  jeho  funkce  vede  ke  ztrátě  produkce  β-1,3-glukanu, 
narušení buněčné stěny a ztráty životaschopnosti houbové buňky. 
V experimentální části jsme jako růstové médium pro BF a planktonické 
buňky (PL) z rodu Candida použili YNB a RPMI 1640. PL i BF jsme inkubovali 
na  96-jamkových  polystyrenových  mikrotitračních  destičkách.  Antimykotická 
aktivita byla  vyhodnocena pomocí  2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]2H-
tetrazolium-5-carboxanilide  (XTT)  testu. Každá  koncentrace  léčiva  byla 
pro každý izolát hodnocena v pentaplikátu. 
Výsledky  ukázaly,  že  MFG  měl  nejvyšší  antimykotickou  aktivitu 
z testovaných  echinokandinů.  Nejcitlivější  byl  vůči  MFG BF  tvořený  druhem 
C. krusei (MIC50 0,125 mg/L), následoval druh C. guilliermondii (MIC50 2 mg/L) 
a nejvíce rezistentní byl C. lusitaniae BF (MIC50 16 mg/L). AND byl nejúčinnější 
proti  BF  C. krusei (MIC50  0,125 mg/L),  dále proti  BF  C. guilliermondii (MIC50 
11
4 mg/L) a nejméně účinný vůči BF C. lusitaniae (MIC50 >256 mg/L). CAS jevil 
největší  účinnost  proti  BF  C. krusei (MIC50 1 mg/L),  dále  C. guilliermondii 
(MIC50 32 mg/L) a C. lusitaniae (MIC50 32 mg/L).
V závěru  našeho  experimentu  jsme  došli  k přesvědčení, 
že echinokandiny působí antimykoticky na biofilmy non-albicans Candida druhů 
in vitro. Biofilm vykazoval vyšší rezistenci než planktonické buňky.
Klíčová slova: echinokandiny, biofilm, Candida, rezistence, XTT
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1 Introduction
Yeasts of the genus Candida are one of the most frequent human fungal 
pathogens.  They  can  occur  on  the  skin  and  on  the  mucous  membrane. 
Some may live on human body with no inconveniences.  Candida may cause 
morbid states in cases of outbreak or in presence of high pathological species. 
They can be responsible either for initiation of superficial mycosis, which do not 
usually have serious course, or cause life-treating systematic infections in some 
cases.  Most  susceptible  to  these  infections  are  patients 
with immunosuppressive  and  cytotoxic  therapy,  broad-spectrum  antibiotics, 
patients suffering from HIV/AIDS and patients in another immunity suppressing 
states,  to  which  the  development  of  a  systematic  infection  poses  a  most 
dangerous threat.
The  occurrence  of  serious  systematic  fungal  infections  caused 
by the genus  Candida is  increasing  nowadays  along  with  their  resistance 
to antimycotic  drugs  used  for  classic  treatment  –  more  and  more  often 
the resistance to azoles antimycotics can be found. The infection can evolve 
into  a very  serious  state  of  candidaemia  associated  with  high  mortality 
especially  in  the  risk  group  of  immunocompromised  patients.  The  state 
of candidaemia is  very difficult  to  treat  because once the infection pervades 
to bloodstream it can spread into liver, spleen and other vitally important organs. 
Surveys reveal  that  C. albicans  is  responsible  for  more than half  of  invasive 
candidaemias  in  Europe,  but  the  frequency  of  non-albicans agents 
from the genus Candida seems to be increasing.
Most of  Candida species create a specific form of growth called biofilm 
which  is  a  structure  of  interconnected  communities  attached  to the surface. 
Biofilm cells are embedded in a matrix of exopolymeric materials. The ability 
of this particular genus to create biofilm is one of the most important virulent 
factors leading to the increase of antifungal resistance. There is also a certain 
possibility  that  change of  the  spectrum of  Candida species  causing  serious 
systematic infections observed in last years is influenced by a higher resistance 
of rare non-albicans Candida species biofilms. 
The main  aim of  our  project  and my thesis  was to  find  susceptibility 
profiles  of  biofilms  produced  by non-albicans Candida species 
to echinocandins. 
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We  observed  the  activity  of  three  different  drugs  from  the  group 
of echinocandins – anidulafungin, caspofungin and micafungin. Echinocandins 
are a relatively new group of drugs with a unique mechanism of action used 
for the treatment of systematic fungal infection. They block the enzyme β-1,3-
glucan synthase. This enzyme is essential for the synthesis of β-1,3-glucan – 
the main component of the fungal cell wall. Disruption of its enzymatic function 
leads to inhibition of glucan production and loss of viability of fungal cell.
We were working with three species:  C. lusitaniae, C. guilliermondii and 
C. krusei.  The  resistance  of  the  Candida biofilm  was  evaluated  in  several 
aspects. We compared resistance of non-albicans Candida species to the same 
echinocandin amongst each other and searched for the highly effective drug 
for every species. Additionally we tested activity of echinocandins also against 
planktonic cells. 
We used the  XTT reduction  assay for  evaluation  of  the  susceptibility 
to echinocandins.
14
2 The genus Candida
The  genus  Candida includes about  a  quarter  of  all  yeast  species 
(Schauer  and  Hanschke,  1999). Yeasts  were  observed  firstly  by  Anton 
van Leeuwenhoek and they were not considered to be living organisms (Huxley, 
1871).  The  first  scientist  who  classified  yeasts  as  living  organisms  was 
Louis Pasteur in 1857.  Significant progress in their  research has been done 
since then.
2.1 Taxonomy of the genus Candida
Candida is  a genus of yeasts which belongs into the kingdom Fungi, 
the phylum  Ascomycota,  the  class  Saccharomycetes and  the  order 
Saccharomycetales.  This  taxonomy  classification  was  firstly  described 
by Christine Marie Berkhout in 1923 (Barnett, 2004).
2.2 The yeast cell
 Yeasts can exist in two morphological forms – as an unicellular spherical 
yeast  or  oval  shaped  pseudohyphae  or  as  filamentous  multicellular  hyphae 
(Hugo et al., 2004). 
They  are  eukaryotic  organisms.  Their  cell  contains  a  nucleus  with 
a nuclear  membrane  encapsulating  the  DNA in  comparison  to  prokaryotic 
cell (Hugo et al., 2004) [Figure 1].
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Figure 1: Diagrammatic representation of the yeast cell
Source: Hugo et al., 2004
In  the  nucleus  is  concentrated  most  of  genetic  material.  The  rest 
of genetic information can occur in the form of plasmids (Hugo et al., 2004 ).
The cell wall has a typical structure containing mainly glucan, mannan 
and chitin. The thickness of this structure is life cycle dependent, but it ranges 
between  100  to  300  nm  (Hugo  et  al.,  2004). Damage  of  this  structure  is 
the main  target  of  most  antifungals.  Cell  wall  structure  is  more  precisely 
described in chapter Echinocandins.
There is a periplasmatic space between the cell wall and cell membrane. 
It contains many proteins, molecules secreted from the membrane and other 
structures. It is also a location for numerous enzymes (Hugo et al., 2004).
The cell membrane is a phospolipid bilayer consisting of proteins as 1,3-
β-D-glucan synthase -  echinocandins target,  phospolipids,  lipids and sterols. 
The main sterol is ergosterol which is the target of amphotericin B (Hugo et al.,  
2004).
Other organelles of the yeast cell,  in our case  Candida species cells, 
are mitochondrions,  endoplasmic  reticulum,  Golgi  apparatus,  ribosomes, 
vacuoles, peroxisomes and other vesicles (Hugo et al., 2004).
Generally the eukaryotic cell is about 10 times bigger than prokaryotic, 
but shape and size are species characteristic. Candida species we tested in our 
study varied in both characteristics. We observed that  C. krusei has oval cells 
with frequent pseudohyphae,  C. lusitaniae has ovoid cells but pseudohyphae 
were  not  so  abundant  and  C. guilliermondii has  smaller  circular  cells  often 
attached to pseudohyphae.
Yeasts can  reproduce  sexually  and  asexually.  However  asexual 
reproduction  called  budding  is  the  most  common  type  (Balasubramanian, 
2004). Sexual reproduction can appear in stress conditions within some yeast 
species  (Neiman,  2005).  For  Candida species  the  asexual  reproduction 
by budding is typical.
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2.3  The  occurrence  of  Candida species  caused 
bloodstream infections
The most frequent agent of human fungal infections is C. albicans (Hugo 
et  al.,  2004;  Parkins et  al.,  2007).  Out  of  other  medically important  species 
several  can  be  named:  C. Parapsilosis,  C. glabrata,  C. tropicalis,  C. krusei, 
C. lusitaniae,  C.  guilliermondii and  C. dubiliensis.  Change  in  the  profile  of 
Candida species  causing  bloodstream  infections  was  observed  during  last 
years – there is decrease of C. albicans and increase of other Candida species. 
Wide  international  survey  revealed  that  in  Europe,  Latin  America, 
Canada  and  United  States  C. albicans  is  responsible  for  more  than half 
of bloodstream  infections  (BSI).  In  Europe  between  years  1997  and  1999 
C. albicans was responsible for 58 % cases of Candida BSIs. Another frequent 
pathogen  was  C. parapsilosis  with  19 %.  In  general  the  profile  was 
55 % C. albicans and  both  C. parapsilosis  and C.  guilliermondii  comprised 
15 % of BSI isolates (Pfaller et al., 2001). 
In another survey from United States from years 1998 – 2000 a rapid 
change of BSI caused by C. albicans was reported. In this survey C. albicans 
compried  45 %  isolates  and  was  followed  by  C. glabrata  with  24 %  and 
C. parapsilosis with 13 % (Hajjeh et al., 2004). The change in the occurrence 
was obvious when this survey was compared to the previous Pfaller  survey. 
We could see there that in United States  C. albicans was also most frequent, 
but its incidence was 55 %.
In  more  current  European  survey  from  years  2002  –  2003  it  was 
observed that  C. albicans was still the most frequent cause of BSI with 51 %. 
However its incidence slightly decreased. Second most common species was 
C. parapsilosis which incidence increased to 23 % and  C. glabrata comprised 
8 % of BSI isolates (Almirante et al., 2005). 
The  newest  international  survey  from  years  2008-2009,  published 
in 2011, revealed changes in the profile of Candida species responsible for BSI. 
In  this  survey  it  was  reported  that  48,4 %  cases  of  BSI  are  caused 
by C. albicans, 18.2 % C. glabrata and 17.1 % by C. parapsilosis (Pfaller, 2011). 
Results  of  non-european  survey  from  India  are  also  interesting. 
There was reported a totally different spectrum of Candida species causing BSI. 
Out  of  all  tested  BSI  isolates  38 %  were  containing C. tropicalis, 
17
21 % C. albicans and  C. glabrata,  C. krusei  and  C. lusitaniae were 
each detected  in  3 %  of  isolates  (Hasan  et  al.,  2007).  Studies  from  other 
regions  are  illustrating  the  diversity  in  broad  spectrum  of  Candida species 
causing infection.
However  extensive  international  surveys  document  the  current  trend 
of increasing incidence of  BSI caused by non-albicans Candida species.
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3 Biofilm
Microorganisms  are  naturally  living  in  cooperating  communities 
like biofilms  rather  than  staying  in  a  state  of  planktonic  free  floating  cells. 
Biofilm is a specific formation of microbial growth which is attached to a biotic 
or abiotic  surface.  Vast  number  of  microorganisms  is  capable  to  organize 
into this form of growth which can develop in many environments. 
The general  theory of biofilm predominance was promulgated in  1978 
in a paper by Costerton, Geesey and Cheng. Biofilm may contain fungal cells, 
bacterial cells or both. Cells create a community consisting of one species or it  
can  occur  as  a  mixed  biofilm  with  more  species  living  in  a  mutual  profit  
(Jenkinson  and  Douglas,  2002).  Cells  in  biofilm  are  encapsulated  and 
connected together  as well  as to the surface with  exopolymeric mass called 
matrix [Figure 2] (Costerton et al., 1987). 
Biofilm can be attached to many kinds of living and non-living surfaces. 
It can  develop  in  human  body  on  biological  surfaces  like  teeth,  epithelium 
of respiratory  system,  heart  valves,  oral  cavity  and  others.  It  is  also  able 
to adhere to surfaces of implanted materials and devices like venous or urinary 
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Figure 2: Candida biofilm Scanning electron micrograph of an infected catheter showing 
C. albicans biofilm
Source: Maki and Tambyah, 2001 http://wwwnc.cdc.gov/eid/article/7/2/70-0342-f2.htm 
catheters,  joint  implants,  stents  or  ocular  glances.  Implanted  materials  and 
devices are less often affected by fungal infection than bacterial. Nevertheless 
if fungal infections appear they are usually difficult to treat (Cox et al., 1988). 
The  frequency of  occurrence  of  biofilms  on  all  kinds  of  surfaces  has  been 
a topic of  many studies and reviews (Dolan,  2001;  Douglas,  2003; Salamon 
et al., 2007; Prester et al., 2004; Raad, 1998; Tumbarello et al., 2007)
Specific  cell  organization  into  biofilm  gains  the  microorganism  many 
benefits.  This  survival  strategy  provides  fungal  and  bacterial  cells 
with the opportunity  to  metabolic  cooperation,  improvement  of  protection 
of the organism  against  the  environment  influences  and  increase  in  its 
resistance against the antimicrobial therapy and host defence.
3.2 Biofilm development
The  manner  of  how  bacteria  and  fungi  form  biofilm  depends 
on the ecosystem and surface they inhabit.  The development can be divided 
into several different stages. Nevertheless, I  have decided to choose division 
into three main stages as optimal [Figure 3]  (Characklis, 1981; Chandra et al, 
2001b, Davies et al., 1996; O'Toole et al., 2000). 
1. Attachment to the surface 
2. Growth and maturation of the biofilm 
3. Dispersal of cell from the biofilm
20
Figure 3: Biofilm development (Author: Pešková)
3.2.1 Biofilm attachment
The attachment of free floating cells to the wet surface is the first step 
of biofilm development.  The solid-liquid  interface as  human tissue and body 
fluid provides an ideal environment for the development and growth of microbial 
biofilm.  There  are  many  characteristics  which  determine  the  most  eligible 
substrate for formation of  Candida biofilm as the roughness of the surface or 
its hydrophobicity (Quirynen and Bollen, 1995; Wimpenny and Colasanti, 1997; 
Nevzatoglu et al., 2007; Teughels et al., 1996).
Planktonic  cells  which  are  floating  cells  existing  individually  in  their 
environment  start  to  adhere  to  the  surface,  e.g.  epithelium,  endothelium, 
materials implanted to the body as catheters etc. 
The attachment can be described in two phases. Initially it is a reversible 
process.  After  a  few seconds  or  minutes  the  process  becomes irreversible, 
if cells  are  not  immediately  separated  from  the  surface.  The  adhesion  is 
provided by weak electrostatics and London-van der Walls forces, interfacial 
tensions  and  covalent  bonding.  Irreversible  changes  in  the  adhesion  are 
accomplished  by  production  of  extracellular  polymers  and  participation 
of hydrolytic enzymes (Zobel, 1943; Costerton et al., 1981). 
After  the initial  colonization the process of  the growth and maturation 
of biofilm starts.
3.2.2 Biofilm growth
Growth and maturation of biofilm is a complex process. Firstly, we can 
observe small randomly distributed colonies of adhered cells on the surface. 
As the  growth  continues,  these  small  colonies  connect  together  and  form 
a continuous layer of biofilm. 
In early and intermediate stages of the biofilm development (attachment 
and growth) many genes of many specific molecules and also genes encoding 
structures  enabling  cell  to  cell  communication  called  quorum  sensing  are 
expressed. It was discovered that Candida albicans quorum sensing molecules 
farnesol and tyrosol, which are responsible for a switch of yeast into filamentous 
state, can have a very complex effect on biofilm (Hornby, 2001; Alem et al., 
2006). Certain amount of tyrosol is secreted in early stages and it is probably 
responsible for hyphal formation. Another  Candida quorum sensing molecule 
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farnesol  has an opposite  effect  and inhibits  the  development  of  filamentous 
forms (Ramage et al., 2001; Alem et al., 2006). However the research of biofilm 
quorum sensing is still in progress.
Once  the  biofilm  is  developed  it  stays  on  the  place  of  its  initial 
attachment,  grows  and  changes  its  shape  and  size.  Because  cells  need 
nutrients and water it has to be created channel systems for them to circulate 
free in the biofilm ( Ramage 2001b, Ramage 2001d). 
3.2.3 Biofilm dispersal
Dispersal  or  detachment  is  a  terminal  phase of  the  biofilm life  cycle. 
As the biofilm grows and the mass increases, the fluid share stress, nutrient 
starvation  and  other  factors  are  leading  to  division  of  biofilm  cells  into 
the environment (Trulear and Characklis, 1982; Hunt et al., 2004). 
Planktonic cells can consequently leave the biofilm at this point, disperse 
and multiply. Afterwards biofilm acts as a nidus of incessant infection (Costeron 
et  al.,  1999).  If  such  dispersal  occurs  repetitively  in  certain  periods,  it  can 
become a reason of many chronic infections relapses.
3.3 Biofilm structure
Biofilm is a very variegated structure. Its heterogeneity is apparent both 
in space and in time. Fundamentally it can be divided into 2 diverse structures – 
the  aggregation  of  cells  and  matrix  -  the  extracellular  polymeric  substance 
(EPS).
Fully developed  Candida biofilm contains a net of yeasts, hyphae and 
pseudohyphae  (Hawser  and  Douglas,  1994).  Hyphal  forms  have  not  been 
observed  in  liquid  cultures  or  on  agar  surface.  This  finding  leads 
to the assumption that contact with solid surface is requisite for development 
of this structure.
Extracellular polymeric substance can either attach cells to the surface 
and hold them together or it can be secreted into the environment. It occupies 
most  (over  95 %) of  the biofilm volume (Zhang,  1998).  EPS contains  water 
(up to 97 %) and many polymeric structures such as proteins, polysaccharides 
and extracellular DNA. However, it is primarily composed of polysaccharides. 
Some  of  them  are  neutral,  but  the  majority  is  polyanionic.  That  is  caused 
by the presence  of  either  uronic  acids  or  ketal-linked  pyruvate  and  specific 
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groups  as  carboxyl,  phosphate  and  sulphate  groups  (Sutherland,  1990;  Al-
Fatani  and  Dougas,  2006;  Suterland,  2001).  Polysaccharides  form  various 
structures in biofilm due to interactions with lipids, proteins, lectins and another 
polysaccharides. It was observed that micoorganisms with mutations involving 
an absence of genes encoding polysaccharides are unable to create real biofilm 
(Allison and Shuterland, 1987; Watnick and Kotler, 1999). However once they 
are  parts  of  mixed  biofilms  it  is  possible  for  one  species  to  live 
in a commensalist  relationship  with  another  species  producing  a  sufficient 
amount of EPS (James et al., 1995).
3.4 Comparison of Candida species biofilms
The  ability  to  form  biofilm  is  a  general  attribute  of  Candida species. 
Nevertheless there are differences in the biofilm architecture, resistance, rate 
of growth, matrix (EPS) composition and substrate demands among species. 
It was observed that  C. krusei create weaker biofilm than  C. albicans  (Tournu 
and  Van  Dijk,  2012).  This  conclusion  was  confirmed  by  our  pre-experiment 
evaluating the ability to create biofilm of species  C. krusei,  C. lusitaniae  and 
C. guilliermondii in comparison with standard C. albicans strain M-61. It became 
apparent that  C. krusei produce less  biofilm (47 –  73 % compare  to  100 % 
growth of M-61) than  C. lusitaniae (more than 100 % compare to M-61) and 
C. guilliermondii (also more than 100 % compare to M-61). Our pre-experiment 
also confirmed the need of longer 72 hours incubation time of C. krusei strains 
to get biofilm of comparable quality to biofilms of C. albicans, C. guilliermondii  
and C. lusitaniae extracted  after  48 hours  long  incubation.  Slower  growth 
of C. krusei biofilm has been observed before (Hasan et al., 2007).
3.5 Biofilm model systems
Many  kinds  of  in  vitro  model  systems  can  be  used  for  observation 
of Candida biofilms and their characteristics, e.g. acrylic strips, catheter discs, 
cylindrical  cellulose  filters,  perfused  biofilm  fermenters  or  microtiter  plates 
(Ramage, 2001; Hawser and Douglas, 1994; Chandra et al., 2001; Baillie and 
Douglas, 1998; Baillie and Douglas, 1998b). In our study  the last mentioned 
model system – the 96-well microtiter plate was used. 
Growth  or  the  fungal  cell  damage  can  be  evaluated  by  two  basic 
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methods  –  XTT assay and  other  colorimetric  methods or  [H3]  leucine  inter-
corporation.  Both  methods  give  a  great  correlation  with  biofilm  dry  weight 
(Hawser and Douglas, 1994). 
Another  issue  necessary  to  be  considered  is  the  fact  that  in  vivo 
the biofilm is influenced by many environment factors – specific composition 
of nutrient in the substrate, certain temperature level and dynamic liquid flow. 
The provision of dynamic condition is essential especially for  Candida species 
biofilms,  because  they  produce  a  significantly  larger  mass  in  dynamic 
than in static  conditions  (Hawser  et  al.,  1998b).  However,  all  mentioned 
conditions can be provided for the 96-well microtiter plate model in laboratory 
by using  the right  growth  medium,  guarantee  of  temperature  stability  and 
by using the rocker to provide gentle shaking.
The 96-well microtiter plate model is very useful for testing of antifungal 
susceptibility of biofilm especially in combination with an evaluation colorimetric 
method  such  as  XTT reduction  assay.  This  method  is  easy  to  use,  rapid, 
relatively accurate  and reproducible  for  number of  Candida  species  isolates 
(Ramage, 2001). The possibility to use this model for high-throughput screening 
and the fact that there is no need for special and expensive equipment make it  
indisputably a great choice for clinical and experimental laboratories.
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4 Resistance of Candida species biofilms
4.1 Biofilm resistance
It is well known fact that biofilms are more resistant to antifungal drugs 
than  planktonic  cells.  The  amount  of  classic  antifungal  treatment  drugs 
(amphotericin B,  fluconazole,  flucytosine,  Itraconazole,  ketoconazole 
and combination of amphotericin B + flucytosine and Fluconazole + flucytosine) 
used to decrease the metabolic activity of  C. albicans  to 50 % biofilm growth 
on PVC discs is five to eight time higher than the amount for planktonic cells 
(Hawser  and  Douglas,  1995).  This  increase  in  resistance  was  proved 
in coincidental  studies  also  for  biofilms  growth  on  other  surfaces  such 
as polystyrene,  silicone elastomer,  polyurethane or  cellulose (Ramage et  al., 
2001b; Chandra et al, 2001b; Lewis et at., 2002;  Baillie and Douglas, 1999). 
Resistance  causes  many  problems  in  chemotherapy  of  Candida 
and other fungal and bacterial infections related with biofilm formations. It has 
been  noticed  that  the  susceptibility  of  biofilm  is  not  only  proved  to  be  low 
against agents from polyenes, allylamines, azoles and pyrimidine analogues but 
also against echinocandins in these formations of growth (Kuhn et al., 2002). 
In any  case  it  seems  that  echinocandins  are  one  of  most  effective  drugs 
in the therapy of Candida infections.
4.1.1 Common mechanisms of biofilm resistance
 Microorganisms  in  biofilm  can  use  many  different  mechanisms 
to increase their resistance against antifungal treatment and the host immunity. 
All  mechanisms of resistance have not  been completely revealed yet, 
but possible mechanisms which can be involved in this process are: restricted 
or decreased penetration of drugs into biofilm, changes in phenotype as a result  
of  low  growth  rate  and  nutrition  limitation  and  surface  induced  expression 
of genes increasing resistance. 
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Restricted penetration
Restricted  penetration  of  drug  could  be  one  of  factors  responsible 
for biofilm  resistance.  The  production  of  matrix  which  provides  adhesion 
to the surface  and  surrounds  cells  could  decrease  the  cell  surface  exposed 
to drugs or the concentration of drug in the biofilm and delay the penetration.
However, many studies have demonstrated that matrix is not the main 
cause of biofilm resistance. There has been an assumption that the penetration 
can  be  delayed,  but  not  significantly  enough  to  be  considered  as  main 
mechanism of resistance (Steward, 1996). The impact of matrix presence was 
also compared in  systems when  Candida  biofilms were  grown in  static  and 
dynamic conditions. Biofilms grown in dynamic conditions under gentle shaking 
produce more matrix. In this comparison no significant difference was found, 
but in separate studies with biofilms grown in flow conditions it was observed 
that resuspended cells with less matrix were more sensitive to amphotericin B 
(Baillie  and  Douglas,  2000;  Baillie  and  Douglas,  1998).  On  that  account 
the possibility that matrix can play a minor part in the biofilm drug resistance 
has to be considered.
Changes  in  phenotype  as  a  result  of  low  growth  rate  and  nutrition 
limitation
Slow growth rate caused by limited supplying of the biofilm by nutrients 
from  the  environment  can  be  another  factor  decreasing  the  susceptibility 
of biofilm to therapy. There are evidences that low biofilm growth is not the only 
cause of  the biofilm resistance,  because increased resistance to  antifungals 
at all grow rates has been observed (Baillie and Douglas, 1998b).
Surface induced expression of genes increasing resistance
The  adhesion  of  free  floating  cells  to  the  surfaces  is  an  initial  step 
of the biofilm development. At this moment cells start to be a part of the biofilm, 
switch their phenotype and activate expression and repression of many genes. 
Upregulation  of genes  encoding  multidrug  efflux  pumps  can  increase 
the resistance. C. albicans has two different types of efflux pumps - ATP-binding 
cassette transporters and major facilitators which are encoded by genes their 
expression  increases  during  biofilm  formation  (Ramage  et  al.,  2002). 
Nevertheless  the  fact  that  mutants  with  single  or  double  deletion  mutation 
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in that study were  highly  susceptible  to  the  treatment  signalizes  that  biofilm 
resistance is a multi-factorial process.
From  other  genetically  determined  mechanisms  of  biofilm  resistance 
the alternation  of  a  target  enzyme  which  seems  to  be  extremely  important 
especially for the antifungal group echinocandins can be mentioned.
4.2 Resistance to echinocandins
 Fungal  pathogens  use  many  different  mechanisms  to  increase  their 
resistance  against  antifungal  therapy.  These  mechanisms  can  differently 
manifest  in  each  species  or  they  can  differently  influence  resistance  even 
in strains of the same species. In biofilms, which are generally difficult to treat,  
it is very important to define mechanisms of their drug resistance and so enable 
the choice and development of effective antimycotic agents.
Factors which are responsible for increase in Candida species resistance 
can be various. In previous chapter general mechanisms that biofilm may use 
to increase its resistance are mentioned. It  is known that there exist specific 
mechanisms which biofilm develops as a protection against certain drugs and 
which can be found also in planktonic cells. For example reduced drug import 
into the cell, modification of drug degradation in the cell, alternation of the target 
enzyme,  changes  in  enzymatic  pathways  or  increased  drug  efflux  to  name 
some.
Although echinocandins are considered to be effective drugs, there have 
been reported cases of to them resistant Candida infections (Miller et al., 2006; 
Hakki et al., 2006). Possible mechanisms of resistance are still being studied. 
Anyway  it  seems  that  increase  amount  of  efflux  transporters  is  not 
the main factor,  because after their genes overexpression caspofungin reacts 
only  with a minimal  increase  in  MIC  (Schuetzer-Muehlbauer  et  al.,  2003). 
Modulation  of  echinocandin  susceptibility  can  be  caused  by  genes  involved 
in chitin synthesis,  protein  mannosilation,  PKC dependent  cell  pathways and 
FKS  genes  regulation.  Nevertheless  the  modulation  of  susceptibility  is 
considered moderate and these mechanisms can be impacts of natural drug 
tolerance and reasons of paradoxical effect (Stevens et al., 2005; Perlin, 2007). 
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4.2.2 Mutation of FKS1 gene - main mechanism of resistance
It  was  discovered  that  Fks1p,  the  major  subunit  of  β-1,3-D-glucan 
synthase, is the main target of  echinocandins (Douglas, 1994) and changes 
in this structure represent important mechanisms of  Candida  species leading 
to decreasing of  susceptibility to  echinocandins (Kurtz  et  al.,  1996;  Douglas, 
1997; Balashov et al., 2006).  
There were tested clinical  isolates from patients whose therapy failed 
or had  only  a  low  response.  It  was  observed  an  amino  acid  substitution 
at Ser645 at HS1 of the subunit Fks1p (Park et al., 2005). As HS1 is designated 
a  „hot  spot  1“,  a  region  of  Fks1p  that  confers  reduced  susceptibility 
to caspofungin.  The change  causes  that  the  glucan  synthase  is  about 
1000 times  less  susceptible  to  the  treatment  (Park  et  al.,  2005).  Changes 
in HS1 region have been observed also for  other  resistant  Candida  species 
including C. krusei (Kahn et al., 2007; Garcia-Effron et al., 2010). However rare 
mutations  of  genes  encoding  Fks  proteins  are,  their  occurrence  increase 
(Pfaller et al., 2011b).
4.2.3 Another mechanisms reducing susceptibility to 
echinocandins
Another mechanism which causes increase of echinocandin antifungal 
activity can be the activation of compensatory pathways like PKC cell integrity 
pathway which leads to elevation of chitin level in the cell (Reinoso-Martin et al.,  
2003). It was also proved that the chaperone protein Hsp90 which is associated 
with  structures  of  many  proteins  and  interacts  with  protein  phosphate 
calcineurin  is  accordingly  integrated  in  processes  regulating  resistance 
to echinocandins (Singh et al., 2009).
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5 Echinocandins
There  are  five  basic  classes of  antifungal  drugs for  treatment  of  life-
threatening  fungal  infections  –  polyenes,  allylamines,  azoles,  pyrimidine 
analogues and echinocandins.  The last  mentioned group of  antifungals  and 
their activity against Candida species is the subject of our experiment. 
Echinocandins  are  a  relatively  new  group  of  antifungal  drugs  active 
against  most  species  from  the  genus  Candida and  also  some  other  fungi. 
Clinically important is especially their activity against the genus  Candida  and 
Aspergillus. 
 Target  of  echinocandins  -  enzyme  β-1,3-D-glucan  synthase  is 
responsible for synthesis of polysaccharid β-1,3-D-glucan which is one of main 
polymers  of the fungal  cell  wall.  The  fungal  cell  wall  is  a  rigid  structure 
which contains mostly glucans. Apart from β-1,3-D-glucan, β-1,4-D-glucan and 
β-1,6-D-glucan, the cell wall composes of chitin, galactomannan, mannan and 
other glycoproteins [Figure 4] (Klis, de Groot and Hellingwerf, 2001; Douglas, 
2001). Nevertheless the major representation in its structure has β-1,3-D-glucan 
which  constitutes  from  30  to  60 %  of  the  cell  wall  of  the  genus  Candida 
(Denning, 2003).
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Figure 4: Structure of the fungal cell wall (Author: Pešková)
Numerous advantages of echinocandins are the reason why they have 
become  one  of  the  first  line  drugs  in  the  treatment  of  Candida  systemic 
infections (Pappas et al., 2004). Advantages of the therapy with echinocandins 
are their broad spectrum of activity,  especially in the genus  Candida,  activity 
against azole-resistant Candida strains, low toxicity, long half-life allowing once 
a day dosing, the fact that the dose does not depend on age, gender or race 
and that they are almost no interactions with other substances on cytochrome 
P450 (Sakaeda et al., 2010; Damle et al., 2008; Colburn et al., 2004; Groll and 
Walsh, 2001; Cancidas PI, 2010; Mycamine PI, 2011; Eraxis PI, 2010).
3.1 Development of echinocandins
Echinocandins are chemically modified microbial  products.  The history 
of their  development began in  1970s.  The first  agent  with  antifungal  activity 
chemically related to echinocandins was a pneumocandin discovered in 1974 
in Germany. Name of this compound was echinocandin B and it was a product 
of  Aspergillus  nidulans (Nyfeler  and  Keller-Schierlein,  1974).  Even  though 
echinocandin B  has  not  been  clinically  used  ever  since,  it  has  become 
a cornerstone for a new line of antifungal drugs - echinocandins.
The first semisynthetic echinocandin approved by U.S. Food and Drug 
Administration  (FDA)  was  caspofungin,  developed  by  Merc  &  Co.,  Inc. 
The approval  by  the  European  Medicine  Agency  (EMEA)  was  received 
in the same year with a trade name Mycamine (Mycamine: EPAR – Summary 
for  the  public).  Caspofungin  is  a  modified  pneumocandin  B0 which  is 
a fermentation  product  of Glarea  lozoyensis  (Letscher-Bru  and  Herbrecht, 
2003).
Caspofungin was followed by micafungin which was invented by the drug 
company Astellas Pharma US, Inc. and approved by FDA in 2005 (Fujie, 2007) 
and EMEA in 2008 as Cancidas (Cancidas: EPAR – Summary for the public).  
Micafungin  was  prepared  by  a  change  in  the  structure  of  hexapeptide 
FR901370 of Coleophoma empedra. 
The  newest  approved  drug  from  the  group  of  echinocandins   is 
anidulafungin.  It  was  originally  developed  by  Vicuron  Pharmaceuticals, 
but it was  later  acquired  by  Pfizer,  Inc.  which  gained  the  approval  of  FDA 
in 2006. It was approved by EMEA in 2007 with a trade name Eclata (Ecalta: 
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EPAR  –  Summary  for  the  public).  Anidulafungin  was  developed  from 
echinocandin B0 produced by Aspergillus nidulans. 
All  echinocandins  are  distributed  in  a  form  of  a  powder  for  infusion. 
Anidulafungin  and  caspofungin  are  provided  as  lyophylised  powders 
for reconstitution  before  infusion.  Micafungin  is  manufactured  as  a  powder 
ready for reconstitution  (Denning,  2003;  Kurtz  and Rex,  2001;  Carver  2004, 
Murdoch and Plosker, 2004).
3.2 Chemical characteristic of echinocandins
Currently clinically used  echinocandins have a structure of semisynthetic 
pneumocandins.  They are lipopeptides with a large molecule with  molecular 
weight  about 1200. We can distinguish two distinct  parts  of  their  structure -  
large amphiphilic cyclic hexapeptide and long N-linked acyl chain of fatty acid 
attached to its skeleton [Figure 5,6 and 7]. 
The composition and size of the side-chain is the characteristic of each 
echinocandin molecule. In the past the side-chain was considered to be a cause 
of haemolytic  activity  of  early  echinocandins.  Later  expedient  modifications 
of this  part  of  the  molecule  led  to  synthesis  of  safe  compounds  without 
haemolytic activity (Klein and Li, 1999).
The  molecule  of  anidulafungin  has  an  alkoxytriphenyl  side-chain. 
Its molecular  weight  is  1140.24.  Caspofungin  has  a  simple  side-chain  and 
molecular  weight  1093.31.  Micafungin  has  a  complex  aromatic  side-chain 
containing 3,5-diphenyl-substituted isoxazole and molecular weight 1270.28.
The  molecular  formula  of  anidulafugin  is  C58H73N7O17,  caspofungin-
acetate formula is C52H88N10O15 · 2 C2H4O2 and micafungin sodium formula is 
C56H70N9NaO23S.
Different  structural  characteristics of  molecules determine their diverse 
solubility.  Caspofungin  (in  form  of  acetate  salt)  and  micafungin  (in form 
of sodium salt) are both free soluble in water, whereas anidulafungin is not. 
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Figure 6: Structure of caspofungin (Author: Pešková)
Figure 5: Structure of anidulafungin (Author: Pešková)
3.3 Mechanism of action of echinocandins
Mechanism  of  action  of  echinocandins  is  based  on  non-competitive 
and concentration-dependent  inhibition  of  enzyme  β-1,3-D-glucan synthase. 
This  unique  enzyme  of  fungi,  which  does  not  occur  in  human  cells, 
is responsible for synthesis of essential carbohydrate component of the fungal  
cell wall – β-glucan. It is a polymer of glucose and it can occur in three main 
forms: as β-1,3-D-glucan, β-1,6-D-glucan and β-1,4-D-glucan. These polymers 
give the shape and mechanical strength to the cell wall and keep the osmotic 
stability.  Changes  in  the  amount  of glucan,  especially  of  β-1,3-D-glucan, 
are leading to the osmotic instability and the cell lysis. 
Glucan synthase is an enzymatic complex bound to the cell membrane 
composed  of  2 subunits.  This  enzyme  and  other  compounds  of  related 
regulatory  pathways  have  been  observed  in  depth  in  many  studies 
with Candida  and other fungal species (Douglas, 1997; Mazur and Baginsky, 
1996; Beauvais et al., 2001). 
One of two compounds of glucan synthase is a catalytic subunit Fksp 
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Figure 7: Structure of micafungin (Author: Pešková)
which  is  a  protein  integrated  in  the  cell  membrane.  It  binds  the  molecule  
of echinocandin and a molecule of the intracellular UDP-glucose. The second 
compound is a regulatory subunit Rho1p, which is a small GTP-binding protein. 
The complex is polymerizing UDP-glucose to glucan and supplying the cell wall 
with new molecules of glucan [Figure 8] (Kang and Cabib, 1986;  Mol et al., 
1994; Shematek and Cabib, 1979; Arellano et al., 1996).
There were found two main forms of the catalytic protein Fksp called 
Fks1p and Fks2p. It was discovered that the gene encoding Fks2p (gene FKS2) 
is highly identical to the gene encoding Fks1p (gene FKS1) (Mazur et al., 1995).  
FKS1 is a cell-cycle dependent gene and its transcription leads to remodulation 
of the cell  wall.  FKS1 plays main role during the vegetative growth whereas 
FKS2 is important for the sporulation. Genes encoding these catalytic proteins 
of β-1,3-D-glucan synthase were first observed in  Saccharomyces cerevisiae 
(Douglas et al., 1994). Later the presence of these two genes in other yeast 
species was researched.  It  was discovered that  C. albicans catalytic subunit 
of 1,3-β-D-glucan synthase is encoded by similar genes as Fks1p and Fks2p 
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Figure 8: β-1,3-D-glucan synthase enzymatic system The picture is illustrating the role of β-
1,3-D-glucan synthase in the synteshesis of β-1,3-glucan
Copied from: Safdar, 2009: Fungal Cytoskeleton Dysfunction or Immune Activation Triggered by 
β-Glucan Synthase Inhibitors
in Saccharomyces cerevisiae (Douglas et al., 1997). 
However, the issue of where exactly echinocandins bind to the enzymatic 
complex has not been fully resolved.
3.4 Pharmacokinetics
Currently  there  are  no  echinocandins  available  for  the  oral  use. 
Anidulafungin, caspofungin and micafungin are for intravenous administration 
only.  There  is  a certain  level  of  the  drug  available  in  plasma  after  oral 
administration, but this amount is insufficient for treatment of fungal infections.  
For  example  the  bioavailability  of  caspofungin  is  even  less  than  0,2 % 
(Caspofungin acetate – FDA advisory committee meeting background,2000).
The recommended dose for treatment of candidaemia for caspofungin is 
70 mg/day followed by a maintenance dose 50 mg/day (Cancidas PI,  2010). 
The recommended  dosage  for micafungin  is  50 mg/day,  100 mg/day 
or 150 mg/day  when  the  dose  100 mg/day  is  recommended  for  treatment 
of candidaemia (Mycamine PI, 2011). Recommended dose for anidulafungin is 
200 mg/day as a loading dose, and 100 mg/day thereafter (Eraxis PI, 2010). 
The  cmax in  plasma  after  intravenous  administration  of  70 – 75 mg 
of caspofungin  and  micafungin  are  relatively  similar,  which  means  12 mg/L 
for caspofungin and 10.9 mg/L for micafungin (Stone et al., 2002; Chandrasekar 
and  Sobel,  2006).  Anidulafungin  reaches  the  cmax 3.55 mg/L  which  is 
considerably lower (Eraxis PI, 2010). For all echinocandins high protein binding 
is typical – more that 95 % (Kofla a Ruhnke, 2011).
Anidulafungin  and  micafungin  are  mostly  eliminated  by  the  liver. 
Caspofungin is mostly eliminated by kidneys. 
From  adverse  effects  of  echinocandins  headache,  fever,  liver  toxic 
effects, histamine release, haemolysis or rush can appear (Cancidas PI, 2010; 
Mycamine PI, 2011; Eraxis PI, 2010).
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3.5 Paradoxical growth effect
An attenuation of antifungal activity in higher concentrations of the drug is 
called „Paradoxical growth effect” or „Eagle effect” [Figure 9]. This phenomenon 
was observed for the first time in 1948 in a study where penicillin bactericidal 
and bacteriostatic activity was tested (Eagle and Musselman,1948). It became 
apparent that this effect can be observed also in higher levels of echinocandins. 
It was  initially  observed  for  the  agent  cilofungin,  which  is  a  derivative 
of echinocandin B (Hall et al., 1988) and thereafter it was described in many 
studies  for  Candida species  with  currently  clinically  used  echinocandins 
(Stevens et al., 2004; Shields et al., 2011; Melo et al., 2007; Chamilos et al., 
2007; Fleischhacker et al., 2008).  The paradoxical effect was observed not only 
in vitro but also in vivo studies (Petraitis et al., 1998).
Performed studies  revealed that  there  are  profile  differences between 
tested  Candida species.  The  concentration  at  which  the  paradoxical  effect 
appears is not the same for tested Candida species and even for strains of one 
species  differences  and  diversity  in  intensity  of  this  effect  were  observed. 
In studies  the  effect  also  appeared  to  be  media  specific.  Hall observed that 
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Figure 9: Paragoxical growth effect The line is representing fungal damage depending on the 
concentration of echinocandins (Author: Pešková)
in RPMI  medium  the  paradoxical  effect  is  more  pronounced  than in  YNB 
medium.
The cause of attenuation of the antifungal activity in higher concentration 
of echinocandins remains unknown. One of supposed reasons of development 
of this effect might be increasing of synthesis of chitin. This contention is based 
on the before mentioned study of Stevens et al. in which he quantified increase 
in the amount of chitin after the exposure to caspofungin. 
Other  potential  mechanism  can  be  up-regulation  of  protein kinase C. 
A rapid  induction  of  the  gene  encoding  protein kinase C  was  observed 
after exposure  to  caspofungin  (Agarwal  et  al.,  2003;   Reinoso-Martin  et  al., 
2003).
Other  mechanisms  responsible  for  paradoxical  effect  could  be FKS1 
mutations  and  up-regulation  of  synthesis  of  β-1,3-D-glucan  synthase. 
Nevertheless it  has not been proved that this mechanism occurs specifically 
after exposure to caspofungin in higher concentrations (Stevens et al., 2005).
Nowadays the research is focused on the clinical implications of findings 
in this area. 
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6 Methods and materials
In the practical part we were measuring the susceptibility of C. lusitaniae,  
C. guilliermondii and  C. krusei biofilm  (BF)  to antimycotics  from  a group 
of echinocandins  (anidulafungin,  caspofungin  and  micafungin).  We  were 
evaluating their  activity against  biofilm and planktonic cells (PL).  For  growth 
of BF  was  necessary  48 hours  (for  C. lusitaniae  and  C. guilliermondii) or 
72 hours long incubation (for C. krusei). Protocol is itemized in appendix.
For evaluation of biofilm susceptibility to echinocandins we used the XTT 
assay.  It  is  a  quantitative  colorimetric  method  which  is  often  used 
for assessment of eukaryotic cell  metabolic activity.  When it was proved that 
it can be also used for testing of fungal cell viability, it becames one of most 
often used methods for evaluating of susceptibility to antifungal drugs (Hawser 
et al., 1998; Meshulam et al., 1995). 
It is based on conversion of tetrazolinum salt XTT (2,3-bis[2-methoxy-4-
nitro-5-sulfophenyl]2H-tetrazolium-5-carboxanilide) into water soluble formazan 
due  to  mitochondrial  dehydrogenase.  This  enzyme  of  respiratory  chain  is 
produced only by living cells with undamaged mitochondrial membrane.
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Figure 10: Schematic plan of the XTT assay for biofilm BF(biofilm), AND(anidulafungin), 
CAS(caspofungin), MFG(micafungin), (Author: Pešková)
6.1 Instrumental and material equipment
Laminar box (Gemini, STERIL)
Incubator at 37 °C (GALLENKAMP, MEMMERT)
Light microscope (OLYMPUS)
Benchtop low speed centrifuge (HETTICH UNIVERSAL)
Benchtop  high  speed  refrigerated  centrifuge  for  microtiter  plates  (HETTICH 
UNIVERSAL)
96-well  microplate  absorbance  reader  (ChroMate,  AWARENESS 
TECHNOLOGY INC)
Electric hot plate with a magnetic stirrer (Cat M 6/1, ZIPPERER GMBH)
Orbital shaker
Vortex (Vortex Genie-2, SCIENTIFIC INDUSTRIES, INC.)
Analytical balance electronic scale (KERN EG)




Centrifuge plastic tubes with a lid (15 mL and 50 mL)
Microcentrifuge safe-lock plastic Eppendorf tube (1.5 mL)
Plastic tissue culture flasks (100 mL)
Petri dishes
Inoculation loop
Bacterial filter (Klari-Flex, WHATMAN)
Automatic pipettes (GILSON)
Automatic multi-channel pipette (Tipor-M, ORANGE SCIENTIFIC)
Automatic pipette tips
96-well polystyrene microtiter plates
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6.2 Chemicals
Yeast nitrogen base with amino acids solution (YNB solution)
RPMI 1640 growth medium with 2 % of glucose
Peptone liquid medium used to preserve isolates
Sabouraud agar with antibiotics (SA+)




Anidulafungin (Ecalta; Pfizer Ltd, US)
Caspofungin (Cancidas; MSD – Merck Sharp and Dohme Ltd, UK)
Micafungin (Mycamine, Atellas Pharma Europe B.V., Holland)
6.2.2 Preparation of solutions and media
Sabouraud agar with antibiotics (SA+)
Contains
30.000 gr of Sabouraud Liquid Medium (with 2 % of glucose)(Scharlau Chemie, 
S.A)
33.300 gr of agar
750.00 μL of Gentamicin Sulfate (Garamycin; MSD, UK)




We mixed Sabouraud liquid medium with agar and refilled with water of injection 
to  1 L.  Whole  volume  was  properly  stirred.  We  sterilized  the  solution 
in autoclave and we added antibiotics after the sterilization. The warm solution 
was poured into Petri dishes and left to solidify.
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Peptone liquid medium used to preserve isolates 
Contains
250.00 μL of glycerol
750.00 μL of peptone water solution (4 g of Peptone from Casein (AppliChem 
GmbH, Germany) in 100 mL water for injection)
Preparation
We had prepared peptone water solution stock.  We took 750 μL of peptone 
solution from the stock and mixed with 250 μL of glycerol in a plastic tube to get 
sufficient amount of medium to preserve one isolate sample.
Yeast nitrogen base with amino acids solution (YNB)
Contains
6.700 gr  of  Yeast  Nitrogen  Base  with  Amino  Acids  (Sigma-Aldrich  Chemie 
GmbH, Germany)
5.000 gr of glycerol
Water for injection
Preparation
We weighed out yeast nitrogen base with amino acids and glycerol, transferred 
it into a bottle and filled up with water to 100 mL. Afterwards we mixed it and 
sterilized it by membrane filtration.
We were using this solution diluted 1:10 as a medium.
RPMI growth medium (RPMI)
Contains
10.400 gr of RPMI 1640 Medium (Sigma-Aldrich Chemie GmbH, Germany) 
100.00 mL  of water for injection 
HEPES buffer (AppliChem GmbH, Germany) 
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Preparation
We dissolved 10.4 gr of RPMI in water pro injection and added as much HEPES 
as we needed to reach pH = 7.2. Then we sterilized it by membrane filtration.
Phosphate buffered saline (PBS)
Contains
Solution 1:
0.745 gr of di-Sodium hydrogen phosphate anhydrous p.Analysis (AppliChem, 
Germany)
0.306 gr of NaCl
Water for injection to 70.00 mL
Solution 2:
0.726 gr of Natruim dihydrogenphosphat-dihydrat (AppliChem, Germany) 
1.314 gr of NaCl
Water for injection to 70.00 mL
Preparation
We prepared both solutions. We were adding Solution 2 into Solution 1 until pH 
reached 7.2. We used membrane filter for sterilization of the solution.
Coenzym Q solution
Contains
0.500 gr of Coenzym Q0 (Sigma-Aldrich Chemie GmbH, Germany)
10.00 mL of acetone 
Preparation




0.025 gr of XTT sodium salt (BioChemica;AppliChem, Germany)
PBS solution to 100 mL
Preparation
We dissolved XTT in 100 mL of PBS solution.  We used membrane filter  for 
sterilization.
6.3 Organisms
Biofilms  of  3  Candida species  were  observed  in  this  experiment: 
C. krusei,  C. lusitaniae and  C. guilliermondii.  Code  names  of  Candida  BSI 
isolates from patients are illustrated in the table [Table1].
Clinical isolates
C. guilliermondii – 
3 strains
C. lusitaniae – 
14 strains
















Table 1: Code names of clinical isolates
Isolates were gathered from the National collection of fungal pathogens 
stationed  at  the  Microbiology  Department,  Medical  School,  National  and 
Kadodistrian University of Athens. 
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6.4 Methods
6.4.1 Storage of clinical isolates
Tubes with clinical isolates were stored in the freezer (-35 °C). 
We had prepared 5 more stock tubes of each sample for our experiment 
by defrosting original  tubes with  isolates and inoculating by them SA+ agar 
plates. Plates were inoculated by spreading the cell suspension over the agar 
surface.  They  were  incubated  for  48 hours  at  37 °C.  We  took  appropriate 
amount  of  cells  after  the incubation,  transferred them with  a loop into  1 mL 
plastic  Eppendorf  tubes  with  peptone  liquid  medium,  vortexed  properly  and 
stored in -35 °C .
6.4.2 Biofilm preparation
We  had  to  defrost  certain  isolate  we  had  chosen for our  week 
experiment.  When  the  sample  was  defrosted,  we  vortexed  it  and  used 
a sufficient  amount  (approximately  30 μL of  suspension)  to  inoculate  a plate 
with Sabouraud agar with antibiotics. We added suspension to the first quadrant 
of the plate with a loop and streaked in order to get single colonies. We let 
the plate incubate for 48 hours at 37 °C .
After 48 hours we removed the plate from the incubator. We took a loop 
and transferred 2 or 3 colonies from the plate into a sterile tissue plastic flask 
filled  with  20 mL of  YNB  solution.  Then  we  left  the  flask  in  the  incubator 
for 24 hours at 37 °C in dynamic conditions. Dynamic conditions were provided 
by using a rocker on speed 8. This way we got a cell suspension which could be 
used to grow biofilm. 
After the incubation we had to wash the cells. At first we put all liquid 
from the  flask  to  a  plastic  tube  and  centrifuged  at  2000 rpm  for  10 min. 
After 10 minutes we took the tube out of the centrifuge and evacuated the used 
YNB  medium.  We  resuspended  pellets  in  10 mL  of PBS  using  the  vortex 
for 20 minutes  on  maximal  speed.  When  the  content  of  the  tube  was 
resuspended  we  centrifuged  again  at  2000 rpm  for  10 min. 
After the centrifugation  we  replaced  PBS  with  10 mL of  RPMI  solution  and 
vortexed for 20 minutes at maximum speed. 
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When the suspension was homogeneous we diluted it with physiological 
solution  1:1000  and  found  out  the  concentration  of  cells  per  a millilitre. 
The Neubauer chamber and a microscope were used for counting cells. 
The  equation  [1]  we  used  for  calculation  of  the  concentration  of  cell  per 
a millilitre was:
c = n/4 x 104 x DF           [1]
                             n........amount of cells on 4 squares of the Neubauer chamber
                             c..............................................................concentration cell/mL
                             DF = 103.................................dilution factor of the suspension
Once we knew the concentration of cells per mL (initial concentration) we 
could  continue with  the  next  step  of  our  experiment  which  was transferring 
microorganisms  into  microtiter  plates.  Prior  to  the  transferring,  we  had  to 
prepare  a  suspension  of  a  concentration  106 cell/mL  in RPMI  solution.  We 
calculated the initial volume of suspension and put it into a 50 mL plastic tube. 
We filled the volume to 28 mL with the RPMI solution. 
The volume of the suspension (= initial volume) needed to be transferred 
into the tube was found out by using this equation [2]:
Vi =Vf x cf / ci     [2]
                                                                Vi................initial volume of suspension
                                                                Vf..................final volume of suspension
                                                                Vf = 28 ml
                                                                ci.......initial concentration of suspension
                                                                ci = c from equation [1] 
                                                                cf..........final concentration of suspensio
                                                                cf = 106 cell/mL
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We had to prepare this suspension in order to have a final concentration 
105 cell/mL in each well of the microtiter plate (except the last column which was 
left  empty  for  blankets).  We  reached  this  concentration  after  filling  wells 
with 100 μL of cell suspension and 100 μL of drug solution. 
Once  the  suspension  had  been  prepared,  we  took  three  96-well 
microtiter  plates  (one  for  each  drug)  and  added 100 μL of  the  suspension 
into each  well  of  columns from 1  to  11  of  every plate  with  a  multi-channel 
pipette. C. lusitaniae and  C. guilliermondii  plates were incubated for 48 hours 
in order to get BF. C. krusei plates were incubated for 72 hours.
6.4.3 Planktonic cell preparation
For  growing PL we reused inoculated SA+ plates  which  we  saved in 
the refrigerator after the biofilm preparation. 
At first we put 2 or 3 colonies from the plate into a sterile plastic tissue 
flask  with  20 mL of  YNB.  This  flask  was  kept  in  the  incubator  for  24 hours 
at 37 °C in  dynamic  conditions.  Dynamic  conditions  were  provided  by using 
the rocker on speed 8.
When  the  incubation  was  finished  we  washed  the  cells  (described 
in the chapter Biofilm preparation). 
From homogeneous suspension we  prepared 1:1000 dilution for  cells 
counting and used equation [1] (described in the part Biofilm preparation). 
The  difference  from method  of  BF  preparation  was  in  calculation  [2] 
for the initial  volume of suspension which had to be transferred to the plate. 
The value for  final concentration (Cf)  was 2 x 106 cell/mL. We used this value 
in order to get concentration 2x105 cell/mL in each well of the microtiter plate 
filled with 100 μL of the suspension and 100 μL of drug solution.
When the suspension had been ready, we took three 96-well microtiter 
plates (one for each drug) and added 100 μL of the suspension into each well 
of columns from 1 to 11 of every plate with the multi-channel pipette .
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6.4.4 Drug plates preparation
The  concentration  of  each  drug  (anidulafungin,  caspofungin  and 
micafungin) was tested in pentaplicate.
It  was  necessary  to  have  2  plates  of  each  drug  for  every  isolate 
(one plate for BF and one plate for PL). Firstly we filled every well in columns 1-
11 of a sterile 96-well microtiter plate with 150 μL of RPMI solution. Then we 
added 150 μL of the drug solution (of concentration 1024 mg/L) to wells 1-5 of 
the row A.  We mixed contents  properly using the multi-channel  pipette  and 
afterwards we transferred 150 μL of the solution from first 5 wells of the row A 
into first 5 wells of the row B. This way we got half concentration in the row B. 
We continued as described to reach the lowest required concentration.
We had to consider that the final concentration of drug on the plate with 
BF and PL will be lower, because we transfered 100 μL of solution from the drug 
plate to 100 μL of the cell suspension on PL or BF plate. That was the reason 
why  we  had  to  add  150 μL  of  the  drug  of  the  concentration  1024 mg/L 
into 150 μL of RPMI to get the final concentration of 256 mg/L
Final concentrations of drugs for our experiment were:
Anidulafungin....................256 - 0.007 mg/L
Caspofungin......................256 - 0.015 mg/L
Micafungin..........................256 - 0.03 mg/L
The design of the plate had to be adapted to the length of the 
dilution line of each drug [Figure 11, 12 and 13]. Drugs were put in rows A – H. 
In the case of anidulafungin we had sixteen dilutions. For caspofungin we had 
fourteen dilutions so we left free wells in columns 6 - 10 of rows G and H (these 
wells were later used as extra positive controls for XTT assay). When we were 
preparing plate with micafungin,  we had thirteen dilutions and we got  empty 
wells  in  columns 6 - 10  of  rows  F,  G  and  H (hese  empty  wells  were  used 
as positive controls as well).
Usually we prepared these plates earlier in advance and we stored them 
in the freezer in -35 °C. In the time of need we took them out, defrosted them 
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and transferred drug solution from them into plates with PL and BF.
ANIDULAFUNGIN
1 2 3 4 5 6 7 8 9 10 11 12
A 256 256 256 256 256 1 1 1 1 1
B 128 128 128 128 128 0.5 0.5 0.5 0.5 0.5
C 64 64 64 64 64 0.25 0.25 0.25 0.25 0.25
D 32 32 32 32 32 0.125 0.125 0.125 0.125 0.125
E 16 16 16 16 16 0.06 0.06 0.06 0.06 0.06
F 8 8 8 8 8 0.03 0.03 0.03 0.03 0.03
G 4 4 4 4 4 0.015 0.015 0.015 0.015 0.015
H 2 2 2 2 2 0.007 0.007 0.007 0.007 0.007
Figure 11: Final concentrations of anidulafungin Numbers represent concentration of drug 
in mg/L
CASPOFUNGIN
1 2 3 4 5 6 7 8 9 10 11 12
A 256 256 256 256 256 1 1 1 1 1
B 128 128 128 128 128 0.5 0.5 0.5 0.5 0.5
C 64 64 64 64 64 0.25 0.25 0.25 0.25 0.25
D 32 32 32 32 32 0.125 0.125 0.125 0.125 0.125
E 16 16 16 16 16 0.06 0.06 0.06 0.06 0.06
F 8 8 8 8 8 0.03 0.03 0.03 0.03 0.03
G 4 4 4 4 4
H 2 2 2 2 2




1 2 3 4 5 6 7 8 9 10 11 12
A 256 256 256 256 256 1 1 1 1 1
B 128 128 128 128 128 0.5 0.5 0.5 0.5 0.5
C 64 64 64 64 64 0.25 0.25 0.25 0.25 0.25
D 32 32 32 32 32 0.125 0.125 0.125 0.125 0.125
E 16 16 16 16 16 0.06 0.06 0.06 0.06 0.06
F 8 8 8 8 8
G 4 4 4 4 4
H 2 2 2 2 2
Figure 13: Final concentrations of micafungin Numbers represent concentration of drug in 
mg/L
6.4.5 Incubation with drugs
 We took all  plates with  BF out  of  the incubator (after the incubation 
for 48 or 72 hours) and prepared plates with PL.
We replaced used RPMI medium on BF plates with a new one before we 
started adding drugs.
When the medium was changed and plates with PL were prepared we 
defrosted  plates  with  drugs.  We  transferred  100 μL  of  the  drug  solution 
into each well of columns 1 – 10 of BF and PL plates (to column 11 we added 
only RPMI). We transferred the drug from a well of a certain number and letter 
into the well of the same number and letter.
We  let  BF  and  PL incubate  with  drugs  for  24 hours  at  37 °C  using 
the rocker on speed 8.
6.4.6 XTT assay
We took PL and BF plates with drugs out of the incubator and centrifuged 
them  for  20 minutes  at  3000 rpm  and  at  15 °C.  Before  the  centrifugation 
we weighted all plates and balanced them very carefully to avoid the damage 
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of the cell layer during the centrifugation. 
We removed the RPMI medium gently from each well  with  the multi-
channel pipette after the centrifugation was finished. At this moment we could 
see whether the biofilm was created properly.
Then we added mixture of  XTT and CoQ solution.  We had prepared 
the mixture of XTT and CoQ solution in advance.  These two reagents were 
in ratio 80 μL of CoQ solution to 1 mL of XTT solution. We transferred 130 μL 
of this mixture into wells of columns 1 - 11 and in wells G and H of column 12 
[Figure 14].  These 2 wells were used as blankets for setting up a microplate 
absorbance reader. 
After  we  had  added  XTT and  CoQ  we  put  plates  into  the  incubator 
at 37 °C and kept them inside for approximately 20 minutes. When these plates 
were  ready  for  reading  (the  colour  of  positive  controls  was  orange)  we 
transferred  100 μL of  the  solution  from  each  well  of  each  plate  into  wells 
of clean  plates.  This  way we  created  a  copy of  BF  and  PL plates  suitable 
for reading in absorbance reader.
 The wavelength we used for measuring was 450 nm.









   HIGH DRUG CONC.
   LOW DRUG CONC.
DRUG + MICROORGANISM
MICROOGANISM
Figure 14: Final design of the plate  for XTT assay P (positiv control), B (blanket)
50
We used this equation [3] to calculate the fungal damage from absorbance 
values:
% fungal damage = 100 - (100 x AE/AC)      [3]
                                                           AE......................experimental absorbance value
                                                           AC................positive control absorbance value
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7 Results
Three  Candida species  were  tested  –  C. guilliermondii  (3  strains),  
C. krusei (13 strains) and C. lusitaniae (14 strains). 
There  was  observed  antifungal  activity  of  anidulafugin,  caspofungin 
and micafungin against biofilm (BF) and planktonic cells (PL). 
To  create  BF  cell  suspension  was  incubated  on  microtiter  plates 
for 48 hours (for  species  C. guilliermondii and  C. lusitaniae)  and for 72 hours 
(for species  C. krusei) at 37 °C in dynamic conditions. Both BF and PL were 
incubated with drugs for 24 hours.
For assessment of the susceptibility to echinocandins was used the XTT 
assay.  The colour conversion was measured at 450 nm with  an absorbance 
reader.  Absorbance  values  of tested  concentrations  of  echinocandins  (every 
drug concentration was repeated in pentaplicate for each strain isolate) were 
processed and converted into the fungal damage. The drug concentration which 
cause fungal damage 50 % was defined as the MIC50. In the end an average 
of MIC50 values  of  tested  species  strains  was  made  and  susceptibility 
for C. lusitaniae, C. guilliermondii and C. krusei was evaluated.
7.1 Candida species susceptibility profiles
In this part are shown charts illustrating susceptibility profiles of Candida 
species to tested echinocandins. 
On charts are plotted values of fungal damage for PL and BF depending 
on the drug concentration. 
Tables  with  values  of  fungal  damages  of  single  tested  strains  are 
itemized in the appendix.
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Figure 15: Susceptibility profile of C. lusitaniae to anidulafungin PL (planktonic cells), BF 
(biofilm), FD (fungal damage)
Average FD for C. lusitaniae Standard deviation
PL [%] BF [%] PL [%] BF [%]
0,007 -13,09 -3,16 8,01 1,22
0,015 4,92 19,73 2,25 2,99
0,030 19,21 31,80 3,87 3,26
0,060 44,20 38,65 3,59 2,61
0,125 85,15 41,96 3,82 3,07
0,250 97,56 43,48 0,84 3,25
0,500 98,34 35,37 0,35 3,15
1,000 98,01 22,97 0,42 2,81
2,000 99,10 20,80 0,25 3,05
4,000 99,34 31,45 0,21 3,76
8,000 98,01 40,79 0,55 2,83
16,000 99,35 48,05 0,23 2,80
32,000 98,99 45,64 0,27 3,56
64,000 99,35 45,22 0,22 2,64
128,000 99,32 40,81 0,20 2,77
256,000 99,36 32,89 0,20 2,83
Concentration of anidulafungin 
[mg/L]:
Table 2: Source data for the figure  Susceptibility profile of C. lusitaniae to anidulafungin
Anidulafungin did not reach MIC50 for biofilm. The closest value to MIC50 
(48.05 %) it  reached was at  the concentration 16 mg/L. MIC50 for  planktonic 
























































concentration of caspofungin [mg/L]
FD
 %
Figure 16: Susceptibility profile of C. lusitaniae to capofungin PL (planktonic cells), BF 
(biofilm), FD (fungal damage), red column marks  MIC50
Average FD for C. lusitaniae Standard deviation
PL [%] BF [%] PL [%] BF [%]
0.030 12.69 10.52 2.29 1.79
0.060 17.72 14.73 3.99 2.02
0.125 19.74 18.13 4.19 2.81
0.250 20.78 18.08 4.19 2.82
0.500 24.20 20.73 5.35 3.22
1.000 67.34 32.37 8.89 7.32
2.000 78.53 30.51 7.90 7.52
4.000 85.43 38.77 6.44 6.71
8.000 80.04 42.75 6.16 7.01
16.000 84.50 41.22 6.37 6.30
32.000 83.69 54.98 6.01 5.77
64.000 89.50 71.61 5.05 5.28
128.000 96.48 90.51 3.76 3.90
256.000 95.41 94.11 4.49 4.38
Concentration of caspofungin 
[mg/L]:
Table 3: Source data for the figure  Susceptibility profile of C. lusitaniae to capofungin
Caspofungin reached  MIC50 for biofilm at 32 mg/L. MIC50 for planktonic 

























































Figure 17: Susceptibility profile of C. lusitaniae to micafungin PL (planktonic cells), BF 
(biofilm), FD (fungal damage), red column marks  MIC50
Average FD for C. lusitaniae Standard deviation
Concentration of micafungin [mg/L]: PL [%] BF [%] PL [%] BF [%]
0.060 69.80 35.44 6.96 5.53
0.125 76.00 30.87 6.55 5.63
0.250 85.16 43.55 5.25 5.82
0.500 89.21 40.10 4.70 6.17
1.000 88.04 26.26 5.49 7.77
2.000 91.28 32.10 4.98 7.67
4.000 92.85 44.36 4.01 6.55
8.000 92.19 45.53 4.10 6.33
16.000 93.36 50.34 3.76 5.78
32.000 92.07 50.01 3.99 5.49
64.000 92.49 48.76 3.99 5.72
128.000 91.76 44.81 4.50 6.16
256.000 90.99 35.44 5.21 7.51
Table 4: Source data for the figure  Susceptibility profile of C. lusitaniae to micafungin
Micafungin  reached  MIC50 for  biofilm  at  the  concentration  16 mg/L. 
For planktonic cells the  MIC50 was less than 0.060 mg/L.
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Figure 18: Susceptibility profile of C. krusei to anidulafungin PL (planktonic cells), BF 
(biofilm), FD (fungal damage), red column marks  MIC50
Average FD for C. krusei Standard deviation
PL [%] BF [%] PL [%] BF [%]
0.007 -12.18 1.47 4.45 3.68
0.015 4.21 12.66 3.69 3.45
0.030 18.12 18.87 7.87 3.09
0.060 37.29 32.67 8.24 4.88
0.125 77.61 50.34 6.60 5.18
0.250 97.13 69.12 1.62 3.90
0.500 98.26 63.78 0.59 4.10
1.000 98.57 55.90 0.41 3.68
2.000 97.89 61.98 1.02 3.52
4.000 99.01 67.39 0.68 3.44
8.000 96.56 68.20 1.01 3.28
16.000 99.37 69.97 0.44 3.79
32.000 98.76 69.30 0.60 4.11
64.000 99.07 69.35 0.53 4.06
128.000 99.24 67.76 0.30 4.19
256.000 99.68 60.58 0.15 5.55
Concentration of anidulafungin 
[mg/L]:
Table 5: Source data for the figure C. krusei susceptibility profile to anidulafungin
Anidulafungin reached MIC50 for biofilm at the concentration 0.125 mg/L. 




























































Figure 19: Susceptibility profile of C. krusei to caspofungin PL (planctonic cells), BF 
(biofilm), FD (fungal damage),  red column marks MIC50
Average FD for C. krusei Standard deviation
PL [%] BF [%] PL [%] BF [%]
0.030 9.25 5.70 2.46 3.07
0.060 22.22 17.31 2.54 2.94
0.125 29.40 17.24 6.28 4.06
0.250 34.33 17.69 8.60 4.46
0.500 32.16 46.00 10.36 7.17
1.000 97.57 59.58 1.10 6.22
2.000 99.25 64.40 0.34 4.99
4.000 99.75 68.48 0.18 3.92
8.000 97.15 68.14 0.59 4.23
16.000 99.92 81.32 0.07 2.56
32.000 99.59 88.37 0.16 1.27
64.000 99.98 94.88 0.01 0.86
128.000 99.99 98.81 0.01 0.38
256.000 99.98 99.47 0.02 0.20
Concentration of caspofungin 
[mg/L]:
Table 6: Source data for the figure Susceptibility profile of C. krusei to caspofungin
Caspofungin reached  MIC50 for biofilm at 1 mg/L. For planktonic cells 

























































Figure 20: Susceptibility profile of C. krusei to micafungin PL (planctonic cells), BF (biofilm), 
FD (fungal damage), red column marks  MIC50
Average FD for C. lusitaniae Standard deviation
Concentration of micafungin [mg/L]: PL [%] BF [%] PL [%] BF [%]
0.060 72.60 39.73 8.88 6.09
0.125 97.29 51.99 0.46 5.20
0.250 97.97 61.66 1.47 5.65
0.500 98.97 59.12 0.42 6.26
1.000 99.27 50.60 0.19 6.92
2.000 99.39 62.40 0.39 4.38
4.000 99.78 62.32 0.19 4.53
8.000 97.55 60.19 0.56 4.92
16.000 99.95 71.86 0.04 3.31
32.000 99.65 72.80 0.20 3.37
64.000 99.74 73.75 0.17 3.01
128.000 99.99 73.42 0.01 3.01
256.000 100.00 69.94 0.00 4.08
Table 7: Source data for the figure  Susceptibility profile of C. krusei to micafungin
Micafungin reached MIC50 for biofilm at the concentration 0.125 mg/L. 
For planktonic cells the  MIC50 was less than 0.060 mg/L.
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Figure 21: Susceptibility profile of C. guilliermondii to anidulafungin PL (planktonic cells), 
BF (biofilm), FD (fungal damage), red column marks  MIC50
Anidulafungin reached MIC50 for biofilm at the concentration 4 mg/L. 
For planktonic cells MIC50 was found at the concentration 1 mg/L.
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Average FD for C. guilliermondii Standard deviation
PL [%] BF [%] PL [%] BF [%]
0.007 4.15 6.61 1.77 0.32
0.015 8.76 13.82 6.09 4.81
0.030 16.94 15.28 2.55 2.07
0.060 23.46 26.10 3.76 3.06
0.125 16.86 26.57 5.32 5.93
0.250 11.41 20.27 5.42 5.36
0.500 14.50 18.83 6.69 2.97
1.000 96.13 8.95 1.17 0.29
2.000 99.78 45.38 0.08 14.96
4.000 100.00 55.09 0.00 12.76
8.000 97.84 64.45 0.45 7.79
16.000 100.00 70.64 0.00 6.14
32.000 99.99 78.11 0.01 4.51
64.000 100.00 76.04 0.00 5.77
128.000 99.99 70.81 0.01 5.05
256.000 99.88 80.28 0.07 5.52
Concentration of anidulafungin 
[mg/L]:




























































Figure 22: Susceptibility profile of C. guilliermondii to anidulafungin PL (planktonic cells), 
BF (biofilm), FD (fungal damage), red column marks MIC50
Caspofungin reached  MIC50 for biofilm at 32 mg/L. For planktonic cells 
MIC50 was at the concentration 1 mg/L.
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Average FD for C. guilliermondii Standard deviation
PL [%] BF [%] PL [%] BF [%]
0.030 13.31 18.29 5.94 5.04
0.060 23.92 26.44 6.10 0.33
0.125 19.48 24.35 2.62 1.78
0.250 19.42 21.83 4.28 3.79
0.500 10.50 25.03 6.05 6.41
1.000 66.56 23.00 8.38 16.26
2.000 93.36 39.18 3.43 20.74
4.000 94.88 44.86 2.59 17.00
8.000 90.22 45.43 4.13 17.68
16.000 87.90 44.26 10.57 14.87
32.000 92.46 50.48 5.14 18.59
64.000 97.37 67.34 1.93 10.48
128.000 100.00 97.13 0.00 1.43
256.000 100.00 99.43 0.00 0.45
Concentration of caspofungin 
[mg/L]:
























































Figure 23: Susceptibility profile of C. guilliermondii to micafungin PL (planktonic cells), BF 
(biofilm), FD (fungal damage), red column marks MIC50
Micafungin reached MIC50 for biofilm at the concentration 2 mg/L. 
For planktonic cells MIC50 was 0.125 mg/L.
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Average FD for C. guilliermondii Standard deviation
Concentration of micafungin [mg/L]: PL [%] BF [%] PL [%] BF [%]
0.060 15.86 25.35 1.69 5.21
0.125 93.82 28.33 1.09 23.72
0.250 98.07 32.11 0.51 25.51
0.500 96.50 35.07 0.87 23.26
1.000 95.72 44.27 1.64 21.83
2.000 96.80 50.49 1.89 14.49
4.000 97.68 51.13 2.07 11.36
8.000 92.59 55.53 3.15 10.43
16.000 98.97 70.54 1.03 8.53
32.000 98.01 68.41 0.80 9.16
64.000 99.64 62.12 0.20 12.23
128.000 98.74 65.06 0.60 12.02
256.000 99.66 54.95 0.14 15.75
Table 10: Source data for the figure C. guilliermondii susceptibility profile to micafungin
7.2 Comparison of susceptibility profiles of Candida 
species to anidulafungin, caspofungin and micafungin
In  charts  are  compared  susceptibility  profiles  of  Candida species  to 
tested echinocandins [Figure 24, 25 and 26]. Lines in charts are representing 
fungal  damage  depending  on  the  drug  concentration  and  illustrating 
























































































Figure 26: Micafungin  - comparison of antifungal activity against C. species BF 
FD(fungal damage)
7.3 Comparison of MIC50 of Candida species 
In the table are compared MIC50 values for biofilm (BF) and planktonic 
cells  (PL).  For  every  comparison  is  calculated  the  statistical  significance 
with non-parametric  Mann-Whitney Test (it was used PC programme InStat 3, 
GraphPad Software). The result of the comparison of two data rows with the 
test was considered as significant when the P value was less than 0.05.
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AND CAS MFG
PL / PL BF / BF PL / PL BF / BF PL / PL BF / BF
0.125 /0.125 0.125 / >256 1/1 1/32 <0.060 /<0.060 0.125 /16
AND CAS MFG
PL / PL BF / BF PL / PL BF / BF PL / PL BF / BF
1 /0.125 4 / >256 1/1 32/32 0.125 /<0.060 2/16
AND CAS MFG
PL / PL BF / BF PL / PL BF / BF PL / PL BF / BF
1/0.125 4 /0.125 1/1 32/1 0.125 /<0.060 2/0.125
C. krusei vs C. lusitaniae MIC [mg/L]
(P=0.0310) (P=0.0011) (P=0.2042) (P=< 0.0001) (P=0.6431) (P=< 0.0001)
C. guilliermondii vs C. lusitaniae MIC [mg/L]
(P=0.0029) (P=0.3643) (P=0.4567) (P=0.8122) (P=0.3666) (P=0.0676)
C. guilliermondii vs C.krusei MIC [mg/L]
(P=0.0475) (P=0.0021) (P=0.9551) (P=0.0503) (P=0.4649) (P=0.0935)
Table 11: Comparison of MIC50 values The P value is determinating the statistical significance, 
PL (planktonic cells), BF (biofilm), AND (anidulafungin), CAS (caspofungin), MFG (micafungin)
 
8 Conclusion and discussion
We tested  the  susceptibility  of  three  non-albicans  Candida species  – 
C. krusei, C. lusitaniae and  C. guilliermondii  as biofilm (BF) and as planktonic 
cells (PL) to anidulafungin (AND), caspofungin (CAS) and micafungin (MFG).
We observed the differences in resistance between species and between 
strains  of  single  species.  There  was  a  large  difference  between 
the susceptibility profile of the PL and BF of all strains. BF was more resistant. 
This reduction of susceptibility in BF is probably caused by specific mechanisms 
as  restricted  or  decreased  penetration  of  drug  into  the  BF,  changes 
in phenotype as a result of low growth rate and nutrition limitation and surface 
induced  expression  of  genes  increasing  resistance  and  other  mechanisms 
which are not revealed yet.
From  tested  echinocandins  the  most  efficient  was  proved  to be 
micafungin.  It  had  50 %  fungal  damage  for  all  three  species  at  lowest 
concentration.  Most  susceptible  to  MFG was C. krusei (MIC50 = 0.125 mg/L), 
then C. guilliermondii (MIC50 = 2 mg/L) and C. lusitaniae BF (MIC50 =  16 mg/L). 
Another tested echinocandin anidulafungin had the same MIC50 for C. krusei BF 
like MFG. Nevertheless the MIC50 for C. guilliermondii and C. lusitaniae BF were 
higher  than  those  for  MFG  (4 mg/L  and  >256 mg/L).  Caspofungin  had 
the lowest antimycotic activity against  C. krusei  and  C. guilliermondii BF from 
all echinocandins  (  MIC50 were  1 mg/L  and  32 mg/L)  and  medium  activity 
against  C. lusitaniae BF (MIC50 = 32 mg/L). From this comparison follows that 
the most resistant was C. lusitaniae and the most susceptible was C. krusei.
According  to  recent  sources  as  susceptible  to  echinocandins  are 
concidered C. krusei isolates with MIC50 lower than 0.25 mg/L and as moderate 
susceptible  with  MIC50 lower  than  0.5 mg/L (Pfaler  et  al.,  2011).  This  value 
seems  to  be  more  accurate  than  CLSI  clinical  breakpoint  (CBS)  2 mg/L 
from 2008  for  all  three  echinocandins  (CLSI,  2008).  Based  on  the  new 
statement BFs of C. krusei isolates from our experiment were resistant to CAS. 
Our experiment has detected low occurrence of resistant C. krusei  BF which 
factually equates to the results of a study published for PL where only singular 
resistance to CAS was observed (Pfaller et al., 2011). In most of the studies 
64
it was proved that the connection between the presence of Fks1, Fks2 and Fks3 
genes encoded mutations and resistance to echinocandins (Pfaler et al., 2011b; 
Imtiaz et al., 2012). When MIC50 ≥ 1 mg/L the FKS mutation occurs and isolates 
are almost always clinically resistant (Pfaller et al., 2011). C. guilliermondii CBS 
are 2 mg/L for susceptible strains and 4 mg/L for moderate susceptible strains 
for echinocandins  (Pfaller  et  al.,  2011c;  CLSI,  2008).  C. guilliermondii  BF 
of tested strains seems to be quite resistant taking into consideration this CBS. 
Especially CAS had a low antimycotic effect against this species.
C. lusitaniae were  significantly  the  most  resistant  species  (P<0.05). 
Taking into account the CBS 2 mg/L which seems to be more of less accurate 
C. lusitaniae BF was resistant to all three echinocandins (Pfaller, 2011c; CLSI, 
2008).
Increased  resistance  of  C. guilliermondii and  C. lusitaniae  compared 
to other  Candida  species was described in previous studies (Pfaller,  2011c). 
BF of all three tested species were also more resistant to echinocandins than 
C. albicans BF  except  C. krusei which  was  less  resistant  to  anidulafungin. 
Our results were compared to data from a previous experiment of the laboratory 
when MIC50 for AND was 0.08 mg/L, for CAS 1.08 mg/L and for MFG 1.79 mg/L 
(Simitsopoulou,  2011).  There  is  a  possibility  that  higher  resistance  of  non-
albicans species can be the reason for their increasing incidence the last years.
Discussed can be also the probability of achievement of sufficient levels 
of drugs in the blood of patients when administered in usual doses for treatment 
of candidaemia. The maximal concentration in blood can be proximetly 8 mg/L 
for CAS and 8.6 mg/L for AND after the loading and maintenance dose (Eraxis 
PI, 2010; Cancidas PI, 2001). This concentration is lower than the MIC50 we 
found  for  C. lusitaniae BF  and  some  C. guilliermondii BF,  which  can  cause 
problems  in the  treatment  of  patients  suffering  for  infections  caused  by  BF 
of these two species.  Since the  concentration  of  MFG can reach 10.9 mg/L 
in blood after the usual  dose,  it  seems to be a good option for treatment of 
the non-albicans species BF associated candidaemia (Mycamine PI, 2011).
To summarize conclusions of our experiment we can say that  Candida 
BF were more resistant than PL. PL had more similar MIC50 than BF which had 
differences across tested species. Most resistant to echinocandins seems to be 
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C. lusitaniae BF.  C. krusei appeared more  susceptible  to echinocandins  than 
both  C. lusitaniae and  C. guilliermondii.  Nevertheless  echinocandins  and 




9 List of abbreviations
FD            fungal damage
BF  biofilm
PL             planktonic cells
BSI  blood stream infection
MFG              micafungin
CAS               caspofungin
AND               anidulafungin
EPS                extracellular polymeric substance
FDA                U.S. Food and Drug Administration
EMEA             European Medicine Agency
XTT             2,3 - bis[2 - methoxy - 4 - nitro - 5 - sulfophenyl] 2H - tetrazolium - 
             5- carboxanilide
YNB                Yeast nitrogen base with amino acids solution 
SA+                Sabouraud agar with antibiotics 
PBS                Phosphate buffered saline solution 
CBS                clinical breakpoint 
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We had one week schedule for our project. From 4 to 6 samples were 
made each week.
Protocol for C. lusitaniae and C. guilliermondii
DAY 0
• Preparation of SA+ with microorganisms from the stock
◦ take one clinical isolate from the freezer (-35 °C)
◦ put  on  a  SA+ plate  and  streak  cells  using  the  loop  to  get  single 
colonies
◦ incubate for 48 hours at 37 °C
DAY 1
• Biofilm preparation I
◦ add 20 mL YNB + 2 % glucose in  100 mL sterile  tissue flask  and 
a loopful of Candida from SA+ plate
◦ let it grow for 24 hours, 37 °C, using a rocker (at speed 8)
DAY 2
• Biofilm preparation II
◦ take out the  sterile tissue flask and transfer into a tube 
◦ separate harvest cells by centrifugation at 2000 rpm, 10 min
◦ do washing step – resuspend cells in 10 mL of PBS and wash once
◦ resuspend washed cells in 10 mL of RPMI solution
◦ vortex 20 min on maximal speed, make 1:1000 dilution, count cells 
and adjust concentration 106 cell/mL using RPMI
◦ add to the 96-well microtiter plate 100 μL of 106 cell/mL to have a final 
concentration 105 cell/mL in rows 1-11
◦ seals plates with parafilm and incubate for 48 hours, 37 °C, using a 
rocker (at speed 8)
DAY 3
• Planktonic cell preparation
◦ add 20 mL YNB + 2 % glucose in 100 mL sterile flask and a loopful 
of Candida (from saved SA+ plate from first day)
◦ grow for 24 hours, 37 °C, using a rocker (at speed 8)
DAY 4
• incubation with drugs
◦ BF
▪ plates with BF centrifuge for 20 min at 3000 rpm (800xg), 15°C
▪ then aspirate supernatants and add 100 μL of RPMI and 100 μL 
of drug (in pentaplicate) 
▪ 1-10 cells+drug, 11 cells only (positive controls)
◦ PL
▪ separate harvest PL grown in YNB by centrifugation at 2000 rpm 
for 10 min
▪ resuspend and wash cells in 10 mL of RPMI, pH 7.2
▪ vortex 20 minutes on maximal speed, make 1:1000 dilution, count 
cells and adjust concentration 2x 106 cell/mL using RPMI
▪ add to the 96-well microtitre plate 100 μL of 2x106 cell/mL to have 
a final concentration 2x105 cell/mL in rows 1-11
▪ 1-10 cells+drug, 11 cells only (positive controls)
◦ incubate PL+BF plates with drugs at 37 °C for 24 hours, using the 
rocker (at speed 8)
DAY 5
• Evaluation of antifungal susceptibility
◦ centrifuge all plates for 20 minutes, 3000 rpm (800xg) 
◦ aspirate medium and add 130 μL of XTT with CoQ
◦ incubate BF and PL cells for 20-30 minutes at 37 °C
◦ tranfer  into  new  clean  plates  and  read  at  450 nm 
by spectrophotometer
Protocol for C. krusei:
DAY 0
• Preparation of SA+ plates with microorganisms from the stock
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
DAY 1
• Biofilm preparation I
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
DAY 2
• Biofilm preparation II
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
DAY 3
• Biofilm plates incubation
◦ incubate BF plates at 37 °C, using a rocker (at speed 8)
DAY 4
• Planktonic cell preparation
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
• Change of RPMI on BF plates
◦ replace used RPMI with 100 μL of a fresh RPMI
◦ seals plates with parafilm and incubate at 37 °C, using a rocker (at 
speed 8)
DAY 5
• Incubation with drugs
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
DAY 6
• Evaluation of antifungal susceptibility
◦ Viz. Protocol for C. lusitaniae and C. guilliermondii
 Values of fungal damages of tested strains
Species  itemized  in  this  appendix  are:  C. lusitaniae,  C. krusei  and 
C. guilliermondii.  There  are  presented six  tables  with  fungal  damage values 
(FD) for each species. Every first three tables are presenting values of FD after  
24 hours incubation with anidulafungin, capofungin and micafungin for biofilm 
plates. Every next three tables are presenting data for planktonic cells. 
Fungal damage is in percents.
Fungal damage of C. lusitaniae strains incubated with anidulafungin – biofilm
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.007 0.60 -12.85 -3.61 5.19 -7.47 -1.97 -5.41 -3.83 -15.41 3.83 1.60 -1.58 -1.94 -3.14
0.015 30.44 22.41 17.54 17.38 32.56 17.30 17.45 11.56 9.30 16.51 14.61 30.06 -9.70 39.66
0.030 48.72 30.01 32.87 25.49 32.56 17.69 28.38 16.70 15.39 16.76 38.59 33.37 13.39 61.03
0.060 48.09 42.17 34.02 27.63 46.00 27.38 26.36 24.68 25.86 40.70 44.40 36.69 26.14 62.67
0.125 58.41 41.72 36.18 29.52 57.26 42.33 37.51 30.80 24.57 25.80 46.97 24.90 38.50 67.11
0.250 56.11 41.19 39.51 26.55 56.60 46.09 26.95 17.74 24.21 23.80 54.61 43.77 39.93 68.43
0.500 57.02 28.48 34.94 20.04 47.88 28.17 24.43 10.24 20.81 15.63 44.02 35.04 32.96 55.12
1.000 41.74 27.66 31.64 7.66 28.54 14.56 19.16 -2.61 8.53 8.71 24.07 20.72 16.39 41.02
2.000 38.50 16.48 21.84 7.95 25.59 2.82 14.48 5.95 6.81 12.70 40.05 9.86 13.67 40.34
4.000 49.83 32.08 30.45 22.62 52.67 10.03 35.04 14.28 23.81 21.39 40.35 31.20 0.43 55.48
8.000 55.67 42.62 41.81 28.26 52.67 17.45 52.32 22.70 30.39 20.59 42.50 39.18 35.37 59.49
16.000 63.61 53.62 41.81 36.16 59.86 29.70 43.47 25.74 37.86 39.88 53.74 39.85 43.86 68.61
32.000 67.08 55.05 46.13 38.12 59.75 25.08 47.98 36.91 31.18 28.28 43.86 22.54 40.02 71.15
64.000 60.25 46.73 42.76 31.73 55.87 24.51 44.37 34.72 30.32 30.36 51.17 40.87 41.16 64.71
128.000 60.13 44.56 40.09 23.88 51.39 19.39 40.36 31.00 29.53 25.51 43.01 38.40 32.48 58.91
256.000 48.37 33.96 44.37 12.28 41.39 11.26 33.33 17.23 9.35 22.02 40.09 37.44 27.47 45.99
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. lusitaniae biofilm incubated with anidulafungin The fungal damage values  are in percents
Fungal damage of C. lusitaniae strains incubated with caspofungin – biofilm
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.030 13.52 27.24 -7.90 18.33 17.33 6.76 3.80 13.47 1.06 7.21 6.61 9.65 12.07 22.74
0.060 20.39 23.88 -8.43 22.28 11.78 8.18 9.24 18.48 23.14 8.91 11.70 8.62 12.70 27.44
0.125 30.22 51.57 -3.53 24.13 7.17 13.74 13.65 23.40 33.61 10.74 8.71 6.52 18.88 22.21
0.250 30.22 51.57 -3.53 24.13 7.17 13.74 13.65 23.40 33.61 10.74 8.71 6.52 18.88 22.21
0.500 32.75 64.40 24.63 28.48 12.76 7.99 9.69 20.15 29.55 15.10 10.54 5.40 14.74 18.21
1.000 27.47 99.64 99.84 18.33 32.40 -0.81 17.08 2.28 14.99 27.54 49.83 10.68 20.11 34.70
2.000 26.90 100.00 99.82 25.51 27.61 9.23 18.29 4.69 12.33 17.92 42.16 12.20 4.94 37.88
4.000 45.99 100.00 100.00 32.85 46.37 9.27 18.34 15.96 16.13 26.23 36.79 13.86 26.94 43.25
8.000 33.87 98.51 100.00 34.12 42.84 3.99 14.95 12.34 22.38 20.75 29.37 12.62 73.83 44.83
16.000 28.40 100.00 100.00 40.03 39.16 16.03 22.91 22.57 32.45 24.57 32.58 12.62 30.78 52.07
32.000 35.54 99.94 100.00 43.08 49.64 35.68 42.94 34.06 40.18 39.15 34.76 38.12 85.12 53.14
64.000 42.89 100.00 100.00 84.17 74.99 30.83 56.13 51.87 52.66 90.90 60.56 95.61 90.97 67.06
128.000 81.96 100.00 100.00 97.61 97.08 98.94 67.69 85.81 77.38 97.74 99.23 100.00 99.69 99.80
256.000 98.07 100.00 100.00 99.93 97.94 98.98 84.00 99.02 94.60 99.98 99.72 100.00 100.00 100.00
Concentration of 
caspofungin [mg/L]
Table : Fungal damage values of C. lusitaniae biofilm incubated with caspofungin The fungal damage values are in percents
Fungal damage of C. lusitaniae strains incubated with micafungin – biofilm
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.060 25.99 18.51 30.42 14.77 40.53 36.51 12.40 20.18 21.45 23.51 36.61 44.59 9.85 44.53
0.125 39.62 26.93 26.93 13.11 43.27 37.47 19.00 31.96 23.52 23.45 37.36 45.04 14.91 45.01
0.250 26.73 32.89 27.44 16.89 51.32 40.41 20.10 36.42 26.05 24.04 43.95 45.35 51.22 29.10
0.500 21.96 16.50 24.17 16.18 44.80 32.67 26.13 26.46 40.40 15.22 39.73 35.57 50.86 41.35
1.000 2.01 -13.34 14.68 15.89 23.28 21.94 12.22 16.58 11.40 6.10 23.36 21.68 56.73 4.27
2.000 16.61 5.72 18.44 11.95 28.60 15.37 6.65 5.87 6.19 11.09 38.57 17.37 87.70 36.57
4.000 33.76 35.82 29.46 20.88 49.69 38.74 27.93 10.94 10.79 7.98 45.94 37.48 89.00 41.30
8.000 26.38 35.66 35.20 11.79 50.36 41.66 28.08 16.90 25.80 21.46 42.32 37.63 94.76 43.57
16.000 35.74 37.51 36.53 21.90 57.01 47.70 37.71 35.01 25.35 24.69 49.71 41.13 92.22 44.28
32.000 32.40 36.38 35.64 26.54 57.26 46.29 41.92 44.79 30.97 25.09 47.67 38.45 81.32 41.91
64.000 41.60 36.13 32.14 35.04 55.31 39.73 33.76 45.36 25.59 23.61 49.41 36.49 82.66 21.06
128.000 29.36 30.37 31.28 32.49 53.13 27.90 25.58 37.38 26.99 16.32 44.21 26.43 84.31 43.33
256.000 24.12 -0.64 16.52 30.25 43.07 21.78 30.11 30.64 12.37 11.96 31.41 17.01 89.41 5.65
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C.lusitaniea biofilm incubated with micafungin The fungal damamges are in percents
Fungal damage of C. lusitaniae strains incubated with anidulafungin – planktonic cells
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.007 2.65 -18.84 1.68 3.21 -12.41 -1.21 -5.41 0.61 -0.39 -0.87 2.91 -4.37 2.14 0.97
0.015 9.90 0.71 16.22 6.25 -7.96 13.39 17.45 4.21 7.02 14.20 18.12 -12.31 11.71 -1.90
0.030 23.49 15.46 26.74 15.05 5.79 22.46 28.38 7.91 11.48 20.91 20.95 58.61 14.81 -2.10
0.060 44.64 36.35 83.18 38.42 48.56 37.81 26.36 17.70 24.17 39.42 53.20 54.48 39.89 53.11
0.125 87.35 92.37 90.57 93.51 96.37 61.08 37.51 77.27 96.37 98.16 81.96 91.69 75.48 96.89
0.250 100.00 99.61 89.49 100.00 98.66 99.82 26.95 98.91 98.83 99.84 99.94 90.48 98.09 98.85
0.500 100.00 98.76 100.00 100.00 99.18 99.76 24.43 99.41 98.03 99.43 98.16 94.86 97.82 98.12
1.000 100.00 95.59 99.91 100.00 98.64 99.22 19.16 99.56 98.68 99.02 98.48 94.65 98.17 97.73
2.000 100.00 100.00 100.00 100.00 99.61 99.92 14.48 100.00 98.75 100.00 99.97 97.16 97.79 98.48
4.000 100.00 100.00 100.00 100.00 99.90 100.00 35.04 100.00 99.45 100.00 100.00 97.63 98.02 99.43
8.000 100.00 99.13 100.00 100.00 99.05 99.48 52.32 98.25 98.15 97.90 98.51 92.06 97.51 98.32
16.000 100.00 100.00 100.00 100.00 100.00 100.00 43.47 100.00 99.56 100.00 100.00 97.23 98.32 99.51
32.000 100.00 99.83 100.00 100.00 99.38 100.00 47.98 100.00 98.70 100.00 99.90 97.09 97.56 98.66
64.000 100.00 100.00 100.00 100.00 99.92 100.00 44.37 100.00 99.44 100.00 100.00 97.81 97.81 99.58
128.000 100.00 100.00 100.00 100.00 99.75 100.00 40.36 100.00 99.34 100.00 100.00 98.17 97.91 99.18
256.000 100.00 100.00 100.00 100.00 99.86 100.00 33.33 99.93 99.48 100.00 100.00 97.70 98.57 99.15
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. lusitaniae planktonic cells  incubated with anidulafungin The fungal damage values  are in percents
Fungal damage of C. lusitaniae strains incubated with caspofungin – planktonic cells
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.030 45.65 27.24 -7.90 3.60 17.74 14.52 4.29 29.80 5.71 6.04 31.19 6.46 17.59 10.90
0.060 57.90 23.88 -8.43 4.70 21.78 23.58 16.06 75.43 11.41 14.05 27.99 7.23 12.08 13.37
0.125 71.20 51.57 -3.53 0.77 22.92 19.88 15.84 75.70 12.27 8.13 22.16 8.96 21.07 16.39
0.250 71.20 51.57 -3.53 0.77 22.92 19.35 15.84 75.70 12.27 7.10 22.16 8.96 21.07 16.39
0.500 82.47 64.40 24.63 -2.99 21.10 5.70 13.85 98.41 15.29 36.52 26.81 9.88 33.08 20.54
1.000 99.71 99.64 99.84 100.00 97.04 57.53 96.66 98.39 96.82 98.45 27.69 19.76 98.54 32.20
2.000 99.76 100.00 99.82 100.00 99.86 100.00 97.87 99.41 97.83 99.63 100.00 95.81 98.92 100.00
4.000 100.00 100.00 100.00 100.00 99.87 100.00 94.64 99.77 97.69 99.85 100.00 95.98 99.62 100.00
8.000 91.50 98.51 100.00 98.05 99.22 98.81 80.86 97.61 93.83 95.14 99.89 97.73 98.24 98.36
16.000 77.85 100.00 100.00 98.49 97.43 99.44 99.10 99.21 81.54 98.42 100.00 99.97 99.73 98.08
32.000 99.92 99.94 100.00 99.98 98.77 90.25 98.22 98.88 98.33 98.30 99.89 98.97 98.96 98.23
64.000 100.00 100.00 100.00 100.00 99.97 100.00 98.72 99.97 99.17 99.24 100.00 99.85 99.73 100.00
128.000 100.00 100.00 100.00 100.00 99.81 99.90 99.02 99.93 99.10 100.00 100.00 99.64 99.66 100.00
256.000 100.00 100.00 100.00 100.00 100.00 100.00 99.37 99.99 99.70 99.63 100.00 99.83 99.87 100.00
Concentration of 
caspofungin [mg/L]
Table: Fungal damage values of C. lusitaniae planktonic cells  incubated with caspofungin The fungal damage values  are in percents
Fungal damage of C. lusitaniae strains incubated with micafungin – planktonic cells
4245 0640 5094 9949 2588 8850 7892 2885 2732 5278 4241 2923 6936 4243
0.060 92.15 59.71 99.49 43.90 97.55 82.83 29.28 17.47 92.37 93.12 97.39 48.29 99.91 99.67
0.125 99.75 80.08 97.67 56.02 98.40 74.00 41.98 18.61 96.66 97.98 99.47 85.52 99.51 98.64
0.250 100.00 99.74 99.62 83.93 99.58 82.64 71.88 29.04 98.35 99.02 100.00 99.40 100.00 99.73
0.500 100.00 99.54 99.46 99.81 99.44 82.34 86.02 95.89 98.19 100.00 100.00 99.16 99.97 99.64
1.000 99.84 99.17 97.07 100.00 99.03 82.74 89.21 99.62 97.69 99.75 100.00 98.90 99.90 98.89
2.000 100.00 100.00 100.00 100.00 99.92 86.95 98.85 99.47 99.08 100.00 100.00 97.82 99.95 99.91
4.000 100.00 100.00 100.00 100.00 100.00 87.15 98.59 100.00 99.70 100.00 100.00 99.19 100.00 100.00
8.000 99.67 100.00 100.00 99.81 99.53 81.66 97.76 99.51 98.05 99.90 99.94 97.18 99.60 98.51
16.000 100.00 100.00 100.00 100.00 100.00 85.97 99.23 99.96 99.61 100.00 100.00 99.35 100.00 100.00
32.000 100.00 100.00 99.79 100.00 99.95 79.11 98.60 99.27 98.99 99.85 100.00 98.87 100.00 99.73
64.000 100.00 100.00 100.00 100.00 100.00 83.32 99.01 99.86 99.26 100.00 100.00 99.83 100.00 100.00
128.000 100.00 100.00 100.00 100.00 100.00 83.03 98.75 99.89 98.96 100.00 100.00 99.55 100.00 100.00
256.000 100.00 100.00 100.00 100.00 100.00 84.70 98.81 99.92 98.68 100.00 100.00 99.85 100.00 100.00
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C. lusitaniae planktonic cells  incubated with micafungin The fungal damage values  are in percents
Fungal damage of C.krusei strains incubated with anidulafungin – biofilm
6865 12414 9346 9908 7394-2 7824 9200 10226 8657 6892 11154 12841 11708
0.007 -12.08 1.10 -8.99 7.46 1.66 9.72 -3.97 -15.24 -21.07 -14.20 27.93 0.23 0.74
0.015 -1.12 7.99 2.87 8.53 12.16 14.55 18.68 7.10 -2.76 -1.72 44.80 11.69 9.14
0.030 -1.93 25.69 15.69 17.09 14.48 12.86 24.66 0.33 7.05 19.67 42.98 13.72 19.65
0.060 -8.83 26.73 32.82 21.10 20.74 29.75 62.91 19.53 35.33 42.43 80.19 32.22 30.40
0.125 18.29 32.86 52.45 48.56 34.47 52.54 65.32 35.53 87.31 74.83 85.07 63.45 28.13
0.250 49.53 52.60 54.73 57.42 82.36 65.24 95.05 84.53 92.37 82.62 64.40 82.50 45.94
0.500 48.71 40.70 54.79 50.38 82.26 54.67 92.50 79.27 82.50 74.05 69.28 74.90 34.18
1.000 38.63 49.70 48.88 39.39 82.11 50.26 79.31 71.25 75.35 67.65 49.90 53.98 39.90
2.000 34.88 61.01 53.67 57.99 86.50 71.27 69.71 71.82 80.31 72.95 49.47 68.61 42.14
4.000 45.82 63.50 53.78 54.76 89.61 70.74 80.49 70.55 88.17 73.04 77.60 73.50 47.13
8.000 52.31 60.94 61.91 47.91 88.25 73.30 85.29 75.06 83.47 75.98 66.26 75.39 48.03
16.000 57.93 60.77 57.93 40.12 89.69 77.37 87.30 82.04 83.13 89.93 53.20 75.45 57.36
32.000 37.07 66.30 50.53 38.92 89.17 74.27 87.99 80.66 81.47 85.74 64.40 81.63 62.41
64.000 37.12 62.81 55.59 38.85 89.97 72.46 88.68 79.58 80.60 84.76 70.14 78.65 58.87
128.000 43.50 50.52 47.93 38.85 90.51 70.21 85.54 86.84 83.32 75.38 65.55 80.20 51.72
256.000 46.11 62.60 54.31 27.23 78.91 67.35 84.74 77.66 71.60 68.59 -3.08 68.54 55.15
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. krusei biofilm incubated with anidulafungin The fungal damage values  are in percents
Fungal damage of C. krusei strains incubated with caspofungin – biofilm
6865 12414 9346 9908 7394-2 7824 9200 10226 8657 6892 11154 12841 11708
0.030 3.69 6.91 -2.71 4.04 4.74 5.23 13.51 4.76 19.87 -3.12 -30.07 -0.05 18.72
0.060 11.82 21.88 51.31 15.51 10.08 16.65 20.04 13.71 22.15 6.15 -3.71 9.04 26.24
0.125 3.63 14.29 61.48 -4.23 26.94 13.84 17.10 17.93 20.69 -6.96 23.30 1.36 35.77
0.250 46.01 13.04 36.83 0.09 8.33 6.22 17.10 17.93 52.46 8.56 -19.31 9.26 35.77
0.500 46.18 55.89 73.72 1.40 37.48 88.36 11.07 24.38 81.60 56.29 88.73 72.84 33.79
1.000 15.71 61.64 47.85 30.44 85.35 88.43 71.74 92.04 85.46 61.96 85.84 70.32 22.36
2.000 58.97 70.96 62.36 66.13 92.11 84.34 76.22 79.27 70.62 76.90 6.04 76.04 44.98
4.000 59.89 72.37 37.72 60.35 93.78 87.23 77.72 84.53 72.14 80.71 51.32 83.64 52.80
8.000 49.47 64.22 32.58 44.15 93.03 79.61 78.85 79.60 77.46 78.22 87.58 80.71 58.24
16.000 84.02 80.48 63.63 75.69 94.72 94.00 85.16 88.75 85.22 80.79 100.00 73.07 75.11
32.000 85.15 89.84 87.72 88.42 92.87 94.09 85.28 90.13 90.13 81.65 100.00 79.83 89.31
64.000 94.28 93.99 88.42 94.81 90.37 99.47 96.56 96.58 94.98 89.05 100.00 91.65 97.75
128.000 99.14 100.00 98.51 99.96 97.29 100.00 99.44 99.74 99.77 94.57 100.00 99.74 98.70
256.000 99.89 100.00 99.21 99.88 99.48 100.00 99.84 100.00 100.00 100.00 100.00 99.89 97.26
Concentration of 
caspofungin [mg/L]
Table : Fungal damage values of C. krusei biofilm incubated with caspofungin The fungal damage values  are in percents
Fungal damage of C. krusei strains incubated with micafungin – biofilm
6865 12414 9346 9908 7394-2 7824 9200 10226 8657 6892 11154 12841 11708
0.060 45.85 35.01 35.32 12.16 65.51 38.29 31.29 40.32 31.87 87.72 65.22 81.92 16.74
0.125 58.00 58.18 38.74 31.73 77.81 61.09 51.33 58.44 57.44 84.27 67.24 79.93 16.86
0.250 51.88 59.46 41.49 52.38 89.25 54.36 69.05 83.24 74.95 83.41 98.75 80.42 21.38
0.500 36.67 69.37 52.84 29.43 90.52 33.80 73.75 83.62 80.04 85.30 78.07 91.02 31.16
1.000 -6.73 58.12 45.70 29.52 90.38 25.41 77.26 66.20 73.80 70.41 90.60 57.29 18.35
2.000 46.23 70.34 65.80 60.18 92.86 70.16 76.21 79.96 74.25 76.00 23.83 67.83 40.62
4.000 46.95 54.87 62.10 62.20 96.36 67.19 79.34 82.85 71.98 79.80 21.63 68.14 44.88
8.000 47.91 59.96 56.13 58.73 92.51 53.05 75.17 74.28 76.18 85.88 8.14 64.09 47.03
16.000 59.03 69.47 67.42 58.76 95.81 65.42 76.67 84.33 81.11 88.50 91.74 73.00 54.20
32.000 64.25 63.23 67.01 55.51 94.65 64.48 87.56 85.15 81.89 88.64 95.04 61.66 60.25
64.000 60.25 61.33 64.53 69.25 98.72 63.80 73.31 89.24 82.89 87.50 88.99 67.00 64.48
128.000 62.53 64.14 67.85 68.96 98.03 61.82 62.73 90.01 88.03 77.87 92.60 66.61 67.51
256.000 44.39 66.12 59.37 65.43 94.05 39.33 79.47 87.88 89.86 76.67 92.84 59.98 67.86
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C. krusei biofilm incubated with micafungin The fungal damage values  are in percents
Fungal damage of C. krusei strains incubated with anidulafungin – planktonic cells
6865 12414 9346 9908 7294-2 7824 9200 10226 8657 6892 11154 12841 11708
0.007 -11.59 -1.14 -24.13 3.94 -19.48 -9.07 -8.37 -6.16 -19.58 -55.60 -2.05 -40.06 3.87
0.015 9.83 20.47 -2.27 -11.51 6.87 3.82 1.59 10.19 -2.54 -26.20 22.06 -20.69 18.85
0.030 11.59 30.95 -0.40 82.20 0.05 98.30 -5.91 11.32 12.26 -18.07 9.90 -13.54 -0.52
0.060 44.05 98.55 30.00 99.39 15.59 100.00 35.46 35.85 5.31 5.76 14.24 3.30 31.97
0.125 71.82 98.22 99.07 99.67 73.32 99.14 59.58 74.24 4.04 88.75 50.67 60.51 97.07
0.250 100.00 99.73 100.00 100.00 92.28 99.95 98.24 98.37 93.36 100.00 100.00 99.83 99.44
0.500 100.00 99.52 100.00 100.00 93.29 100.00 94.41 97.69 93.54 99.33 100.00 98.75 98.09
1.000 99.95 99.14 100.00 100.00 95.85 98.29 94.99 97.95 97.98 100.00 100.00 98.41 98.87
2.000 100.00 99.64 100.00 87.69 95.08 100.00 99.20 99.21 88.34 100.00 100.00 99.70 100.00
4.000 100.00 100.00 100.00 100.00 93.51 100.00 100.00 99.95 90.73 100.00 100.00 100.00 100.00
8.000 98.59 98.36 100.00 98.00 88.19 99.24 96.43 96.16 85.83 98.90 100.00 98.02 96.09
16.000 100.00 100.00 100.00 100.00 97.18 100.00 100.00 100.00 93.24 99.51 100.00 100.00 100.00
32.000 100.00 99.70 100.00 100.00 91.54 100.00 98.83 98.26 94.20 99.76 100.00 99.66 100.00
64.000 100.00 99.79 100.00 100.00 92.87 100.00 97.50 99.89 95.10 100.00 100.00 100.00 100.00
128.000 100.00 98.19 100.00 100.00 95.96 100.00 97.92 99.11 97.55 100.00 100.00 99.57 100.00
256.000 100.00 99.85 100.00 100.00 98.51 100.00 98.08 99.53 99.28 100.00 100.00 99.70 100.00
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. krusei planktonic cells  incubated with anidulafungin The fungal damage values  are in percents
Fungal damage of C. krusei strains incubated with caspofungin – planktonic cells
6865 12414 9346 9908 7394-2 7824 9200 10226 8657 6892 11154 12841 11708
0.030 21.86 16.30 2.21 6.13 -7.52 14.14 3.92 4.21 10.35 32.41 16.29 5.93 12.41
0.060 39.59 25.02 11.72 35.93 6.95 26.58 23.62 16.86 21.49 30.51 24.44 13.59 29.56
0.125 70.88 98.64 41.23 41.71 5.40 22.97 11.65 7.20 14.91 26.46 20.68 17.39 13.30
0.250 99.44 99.90 76.23 84.84 5.40 18.84 11.65 7.20 11.84 17.46 19.54 17.70 13.30
0.500 99.86 99.48 99.74 99.96 1.91 5.82 2.02 1.53 16.39 -2.02 12.51 13.00 5.85
1.000 100.00 99.74 99.28 100.00 97.66 99.37 94.77 99.54 85.40 100.00 100.00 99.91 88.47
2.000 100.00 99.58 99.74 99.68 95.64 100.00 99.92 100.00 96.21 100.00 100.00 99.88 98.54
4.000 100.00 100.00 100.00 100.00 97.37 100.00 100.00 100.00 98.69 100.00 100.00 100.00 100.00
8.000 98.26 98.97 97.26 100.00 91.42 97.70 95.93 98.47 93.37 99.33 99.65 99.94 96.84
16.000 100.00 100.00 100.00 100.00 99.83 100.00 100.00 100.00 98.87 100.00 100.00 100.00 100.00
32.000 100.00 98.87 100.00 100.00 99.14 100.00 100.00 99.85 97.84 100.00 100.00 99.60 98.66
64.000 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 99.91 100.00 100.00 100.00 99.84
128.000 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 99.92
256.000 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Concentration of 
caspofungin [mg/L]
Table : Fungal damage values of C. krusei planktonic cells  incubated with caspofungin The fungal damage values  are in percents
Fungal damage of C. krusei strains incubated with micafungin – planktonic cells
6865 12414 9346 9908 7394-2 7824 9200 10226 8657 6892 11154 12841 11708
0.060 100.00 100.00 100.00 100.00 -2.59 49.25 96.86 99.53 99.40 100.00 100.00 100.00 31.28
0.125 99.27 99.13 97.23 98.66 94.20 96.83 94.69 95.45 99.60 98.30 99.13 99.17 97.18
0.250 100.00 100.00 99.86 100.00 96.79 100.00 99.26 99.42 99.96 100.00 100.00 100.00 76.20
0.500 100.00 100.00 99.29 99.68 98.22 99.93 97.94 98.68 99.95 99.79 93.17 100.00 99.96
1.000 99.92 99.93 99.15 99.90 97.53 100.00 99.43 98.44 100.00 99.62 100.00 99.76 99.29
2.000 100.00 100.00 100.00 100.00 98.86 100.00 93.77 98.52 99.60 99.83 100.00 100.00 100.00
4.000 100.00 100.00 100.00 100.00 100.00 100.00 96.92 100.00 100.00 99.79 100.00 100.00 100.00
8.000 100.00 98.32 98.58 99.81 96.00 96.97 92.06 97.39 99.68 98.86 99.59 97.68 99.34
16.000 100.00 100.00 100.00 100.00 100.00 100.00 99.31 100.00 100.00 100.00 100.00 100.00 100.00
32.000 100.00 100.00 100.00 100.00 99.06 100.00 96.97 98.68 100.00 99.86 100.00 100.00 100.00
64.000 100.00 100.00 100.00 100.00 100.00 100.00 98.06 100.00 100.00 100.00 100.00 100.00 98.06
128.000 100.00 100.00 100.00 100.00 99.95 100.00 99.83 100.00 100.00 100.00 100.00 100.00 100.00
256.000 100.00 100.00 100.00 100.00 99.95 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C. krusei planktonic cells  incubated with micafungin The fungal damage values  are in percents
Fungal damage of C. guilliermondii strains incubated with anidulafungin – biofilm
99 111 112
0.007 5.85 4.91 9.08
0.015 13.67 11.10 16.69
0.030 15.86 19.76 10.21
0.060 23.52 28.62 26.18
0.125 29.11 26.17 24.44
0.250 18.47 19.07 23.27
0.500 10.56 10.16 35.77
1.000 8.66 9.24 27.64
2.000 70.06 48.30 17.76
4.000 84.81 56.45 24.01
8.000 84.65 71.71 37.00
16.000 86.09 79.12 46.72
32.000 88.78 84.99 60.55
64.000 89.32 80.02 58.79
128.000 87.13 83.29 42.02
256.000 83.20 83.71 73.95
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. guilliermondii biofilm  incubated with anidulafungin The fungal damage 
values  are in percents
Fungal damage of C. guilliermondii strains incubated with caspofungin – biofilm
99 111 112
0.030 7.33 24.74 22.78
0.060 24.92 26.01 28.40
0.125 19.68 25.51 27.86
0.250 20.01 11.91 33.57
0.500 22.78 15.23 27.29
1.000 34.14 15.59 30.40
2.000 47.71 21.59 30.65
4.000 57.29 28.44 32.43
8.000 56.30 28.68 34.55
16.000 59.12 39.39 44.26
32.000 65.62 57.62 35.34
64.000 77.55 79.90 57.13
128.000 99.71 95.58 96.11
256.000 100.00 98.66 99.62
Concentration of 
caspofungin [mg/L]
Table : Fungal damage values of C. guilliermondii biofilm  incubated with caspofungin The fungal damage 
values  are in percents
Fungal damage of C. guilliermondii strains incubated with micafungin – biofilm
99 111 112
0.060 41.76 24.58 26.12
0.125 40.54 11.31 33.13
0.250 49.88 10.27 36.20
0.500 54.52 14.87 35.83
1.000 54.12 17.02 61.69
2.000 53.74 46.33 51.41
4.000 58.63 60.34 34.43
8.000 50.32 65.51 50.77
16.000 70.51 72.23 68.88
32.000 70.12 67.84 67.28
64.000 64.79 60.69 60.88
128.000 64.50 59.22 71.45
256.000 62.54 46.18 56.14
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C. guilliermondii biofilm  incubated with micafungin The fungal damage values 
are in percents
Fungal damage of C. guilliermondii strains incubated with anidulafungin – planktonic cells
99 111 112
0.007 5.94 0.61 5.91
0.015 19.19 8.99 -1.89
0.030 21.42 16.80 12.60
0.060 30.67 21.69 18.02
0.125 27.34 13.22 10.02
0.250 21.34 10.19 2.70
0.500 18.47 23.58 1.45
1.000 96.72 97.80 93.88
2.000 99.76 99.66 99.92
4.000 100.00 100.00 100.00
8.000 97.16 97.65 98.70
16.000 100.00 100.00 100.00
32.000 100.00 99.97 100.00
64.000 100.00 100.00 100.00
128.000 99.96 100.00 100.00
256.000 99.76 99.87 100.00
Concentration of 
anidulafungin [mg/L]
Table : Fungal damage values of C. guilliermondii planktonic cells  incubated with anidulafungin The fungal damage values 
are in percents
Fungal damage of C. guilliermondii strains incubated with caspofungin – planktonic cells
99 111 112
0.030 22.78 2.36 14.80
0.060 33.41 12.55 25.80
0.125 23.21 14.42 20.81
0.250 22.40 10.99 24.89
0.500 11.04 70.95 9.96
1.000 50.96 79.66 69.07
2.000 99.19 93.57 87.31
4.000 99.90 93.44 91.29
8.000 96.89 91.13 82.66
16.000 98.47 77.32 70.80
32.000 97.60 87.32 77.32
64.000 100.00 93.60 98.50
128.000 100.00 100.00 100.00
256.000 100.00 100.00 100.00
Concentration of 
caspofungin [mg/L]
Table : Fungal damage values of C. guilliermondii planktonic cells  incubated with caspofungin The fungal damage values 
are in percents
Fungal damage of C. guilliermondii strains incubated with micafungin – planktonic cells
99 111 112
0.060 23.66 17.56 14.17
0.125 93.09 95.95 92.41
0.250 97.05 98.67 98.48
0.500 95.83 98.22 95.45
1.000 96.29 98.22 92.64
2.000 98.47 98.89 93.03
4.000 99.95 99.56 93.54
8.000 95.53 95.95 86.29
16.000 100.00 100.00 96.91
32.000 98.73 98.89 96.40
64.000 99.69 99.96 99.27
128.000 98.88 99.69 97.64
256.000 99.64 99.91 99.44
Concentration of micafungin 
[mg/L]
Table : Fungal damage values of C. guilliermondii planktonic cells  incubated with micafungin The fungal damage values  are 
in percents
